 March 28, 2011
Phase I/II Study of Dasatinib in Combination with Zoledronic 
Acid for the Treatment of Breast Cancer Bone Metastasis 
BMS Protocol Number: CA180094  
Stacy Moulder, M.D., M.S.C.I. 
Breast Medical Oncology, Unit 1354 
The University of Texas M.D. Anderson Cancer Center 
P.O. Box 301438 
Houston, TX 77230-1439 
 
Physical address: 
1155 Pressler Street 
Houston, TX 77030 
 
Telephone: 
(713) 792-2817 
 
Fax: 
(713) 794-4385 
 
email: 
smoulder@mdanderson.org 
 
Protocol Version/Date: Version 8, 03/28/2011 
Protocol Revision Date:  03/28/2011 
 
Co-principal Investigator:   Marjorie Green, M.D. 
 
Co-investigators:    Gabriel Hortobagyi, M.D. 
Lajos Pusztai, M.D . 
 Statistician:     Kristine Broglio/Marcy Johnson, M.S.  Imaging Collaborator:   Juri Gelovani, M.D., PhD
 
 Laboratory Collaborator:   Bryant G. Darnay, PhD 
1 
 March 28, 2011
 
TABLE OF CONTENTS 
BMS Protocol Number: CA180094 .................................................. 1  
PROTOCOL SYNOPSIS....................................................................  7
16
16
16
16
16
17
17
17
17
18
18
19
19
19
19
20
20
20
20
22
24
25
26
27
281 INTRODUCTION ...............................................................  
1.1 Hypothesis .......................................................................  
1.2 Background......................................................................  
1.2.1  Bone Metastasis in Patien ts with Breast  Can cer ..........................  
1.2.2  The Role of Src in  Breast Ca ncer ...................................................  
1.2.3  The Role of Src in the Regulation of Osteoclast Function...........  
1.2.4  The Role of PDGF in  Bone Metastasis...........................................  
2 OVERVIEW OF STUDY DRUGS ......................................  
2.1 Dasatinib ..........................................................................  
2.1.1  Preclinical Anti-tu mor Activity........................................................  
2.1.1.1  In Vitro Molecu lar Studi es...............................................................  
2.1.1.2  In Vivo Studies .................................................................................  
2.1.2  Preclinical Toxicol ogy.....................................................................  
2.1.3  Clinical Pharmacokinetics ..............................................................  
2.1.3.1  Absorption........................................................................................  
2.1.3.2  Distribution.......................................................................................  
2.1.3.3  Metabolism.......................................................................................  
2.1.3.4  Eliminat ion .......................................................................................  
2.1.4  Clinical Experience with Dasatinib.................................................  
2.1.5  Safety of Dasatinib in  Clinical Studies ...........................................  
2.1.6  Laboratory Abno rmalities ...............................................................  
2.1.7  Anticipated Ad verse Even ts ...........................................................  
2.1.8  Phase I experience in  Solid Tu mors ..............................................  
2.2 Zoledronic Acid................................................................  
3 STUDY RATIONALE.........................................................  
2 
 March 28, 2011
3.1 Rationale for the Use of Dasatinib in Combination 
with Zoledronic Acid for the Treatment of 
Hormone Receptor Negative Metastatic Breast 
Cancer and in Combination with Antiestrogen Therapy in Patients wi th Hormone Receptor 
Positive Breast Cancer.................................................... 28
 
29
 32
32
33
33
34
35
35
35
35
36
36
36
36
36
38
40
40
41
41
41
42
423.2 Rationale for the Use of N-telopeptide of Type I Collagen (Ntx) as the Primar y Endpoint to Measure 
Therapeutic Response ....................................................
 
4 OVERVIEW OF STUDY DESI GN AND EVALUATION ....  
4.1 Dose-finding and Cohort Definitions .............................  
4.2 Phase I Study Design ......................................................  
4.2.1  Definition of Dose Limiting Toxicity...............................................  
4.3 Phase II Study Design .....................................................  
5 STUDY OBJECTIVES.......................................................  
5.1 Primary Objective ............................................................  
5.1.1  Phase I: .............................................................................................  
5.1.2  Phase II: ............................................................................................  
5.2 Secondary Objective(s)...................................................  
5.2.1  Phase I: .............................................................................................  
5.2.2  Phase II: ............................................................................................  
6 SELECTION OF PATIENTS .............................................  
6.1 Inclusion Criteria .............................................................  
6.2 Exclusion Criteria ............................................................  
7 TREATMENT OF SUBJECTS ..........................................  
7.1 Study Registration...........................................................  
7.2 Study Treatment ..............................................................  
7.2.1  Phase I ..............................................................................................  
7.2.2  Phase II .............................................................................................  
7.3 Drug Dosing and Routes of Administration..................  
7.3.1  Dasatin ib...........................................................................................  
3 
 March 28, 2011
7.3.2  Zoledronic Acid................................................................................  42
43
43
44
44
45
 45
45
46
47
49
49
53
53
53
54
54
54
54
55
55
55
55
55
55
55
55
56
567.4 Dose Modifications..........................................................  
7.4.1  Dasatin ib...........................................................................................  
7.4.2  Dose Modifications fo r Zoledroni c Acid ........................................  
7.5 Discontinuation of Therapy ............................................  
7.5.1  Follow up After Discontinuation  of Protocol Therapy:.................  
7.6 Prohibited and Restricted Therapies During Study......  
7.6.1  Prohibited The rapies .......................................................................  
7.6.2  Restricted Therapi es .......................................................................  
7.7 Concomitant Therapy......................................................  
8 STUDY PROCEDURES ....................................................  
8.1 Evaluation and visit schedule ........................................  
9 EFFICACY AND SAFETY ASSESSMENTS.....................  
9.1 Efficacy Assessment.......................................................  
9.1.1  N-telopeptide of Type  I Collagen (Ntx)...........................................  
9.1.2  Measurement of Tumor Response ....... Error! Bookmark not defined.  
9.2 Safety Assessment..........................................................  
10 STUDY DRUG(S) ..............................................................  
10.1  Dasatinib Product Identification.....................................  
10.2  Packaging and Labeling..................................................  
10.3  Storage, Handling and Dispensing of Dasatinib...........  
10.3.1  Storage .............................................................................................  
10.3.2  Handling and Dispos al ....................................................................  
10.3.3  Dispensing .......................................................................................  
10.4  Drug Ordering and Accountability .................................  
10.4.1  Initial Orders.....................................................................................  
10.4.2  Re-suppl y .........................................................................................  
10.5  Dasatinib Accountability.................................................  
10.6  Destruction of Dasatinib .................................................  
10.7  Zoledronic Acid................................................................  
4 
 March 28, 2011
10.7.1  Supply...............................................................................................  56
56
57
58
59
59
60
62
62
62
63
63
64
64
64
64
64
65
65
65
66
66
68
79
8010.7.2  Preparat ion
.......................................................................................  
10.7.3  ANTICIPATED TOXICITY .................................................................  
10.7.3.1  Osteonecrosis of the Jaw (ONJ).....................................................  
10.7.3.2  Monitoring of Renal Func tion.........................................................  
11 ADVERSE EVENTS..........................................................  
11.1  Reporting of SAEs...........................................................  
12 STATISTICAL METHODOLOGY......................................  
12.1  PHASE I ............................................................................  
12.2  Phase II .............................................................................  
12.2.1  Cohort A: Patients with modera te or high baseline levels of 
Ntx:....................................................................................................  
12.2.2  Cohort B: Patients with low levels of  Ntx:.....................................  
13 ADMINISTRATIVE SECTION ...........................................  
13.1  Compliance with the Protocol and Protocol 
Revisions..........................................................................  
13.2  Ethical Considerations and Informed Consent.............  
13.3  Records and Reports ......................................................  
13.4  Institutional Review Board (IRB) ....................................  
13.5  Records Retention...........................................................  
14 CORRELATIVE STUDIES ................................................  
14.1  Biologic Characterization of Response Using 18F-
FDG PET:..........................................................................  
14.2  Determination of Molecular Correlates in Paraffin Embedded or Frozen Tissue: .........................................
 
14.3  Banking of Blood Samples .............................................  
REFERENCES.................................................................................  
APPENDIX 1  LIST OF ABBREVIATIONS ....................................  
APPENDIX 2  KNOWN INDUCERS & INHIBITORS OF 
ISOENZYME CYP3A4.......................................................  
5 
 March 28, 2011
APPENDIX 3  DASATINIB PATIENT DIARY FOR 
STUDY:CA180094 ............................................................  81
APPENDIX 4   STUDY MONITORING PLAN FOR 
COLLABORATING SITES…............ .............................. ...................82 
 
6 
 March 28, 2011
 
PROTOCOL SYNOPSIS 
 
Protocol Title:  
Phase I/II Study of Dasatinib in Co mbination with Zoledronic Acid 
for the Treatment of Breas t Cancer Bone Metastasis  
# Sites and Names: Multicenter: M.D. Anderson Cancer Center, Un iversity of Chicago, and Duke University  
 Phase I Study Schema:  
 
 
 
 Phase I Dose Escalation Schema 
Dosing cohort 1:
•Three patients will be initially treated in cohort 1.
•If <1 out of 3 patients in cohort 1 develop DLT, 3 additional patients will 
be accrued to cohort 2. 
•If If < 1 out of 3 patients in cohort 2 develop DLT, 3 additional patients will 
be accrued. 
•If >2 out of 3 or > 2 out of 6  pa ti ents  de ve lop DLT, furthe r ac crual wi ll 
continue until 6 patients are treated at the next lower dosing cohort.
•If <1 out of 6 patients develop DLT, this dose level will be deemed the 
recommended phase 2 dose (RP2D) and the phase II portion of the trial 
will open to accrual.
Dosing Cohort –1 :
•Three patients will be initially treated
•If <1 out of 3 patients develop DLT, 3 additional patients will be accrued.
•If <1 out of 6 patients develop DLT, this dose level will be deemed RP2D 
and the phase II portion of the trial will open to accrual.
•If >2 out of 3 or 2 out of 6 patients develop DLT, the study will be closed 
due to intolerability of the combination
P h ase I Dr ug  Adm in is tr ati on
S tand ard  do sing 
(se e sect ion 7 .3.2 )1 00  mg  poda i l y 1S tand ard  do sing 
(se e sect ion 7 .3.2 )70  m g po daily -1Zoledr onic Ac id Da sa tin ib Dos ing  C ohor t
7 
 March 28, 2011
Phase II 
Study Schema 
1. Zoledronic acid to be administered at standard doses as defined in section 7.3.2. 
2. Ntx= N-telopeptide of Type I Collagen   
 
 Study Design:  This is an open label, Phase I/II, dose escalation study to evaluate the safety and tolerabili
t
of dasatanib in combination with a standard 28- day cycle of zoledronic acid in patients wi t
metastatic breast cancer to bone.   Zoledronic acid will be administered as a 15-minute infusion on da y 1(+/- 48 hours) of 
28-day cycle. The dose of zoledronic acid administered will be calculated using t
h
standard dosing guidelines outlined in section 7.3.2. 
Dasatinib will be taken by mouth using a daily  dosing schedule on days 1-28 of each cyc l
(i.e. continuous dosing).   The primary objective of the phase I portion of this trial will be to determine the RP2D f
o
dasatinib in combination with zoledronic acid.   The first 3 patients will be treated with 100 mg  of dasatinib daily in  combination with f
u
dose zoledronic acid. If < 1 patient develop(s) DLT within  cycle one of therapy, then 
additional patients will be accrued.   If <
 1 of 6 enrolled patients experiences D LT, then this will be deemed the RP2D a n
accrual will begin for the phase 2 portion of the trial.  
If > 2 patients develop DLT during initial accr ual to any cohort (n =3) or during the do s
expansion (n=6), further accrual will continue at the next lower dosing cohort until a total o
six patients are treated at  the lower dosing cohort.  
If > 2 patients develop DLT during accrual to  cohort –1, the study will be closed due tPhase II 
Initial Registration 
Baseline measurement of Ntx2Patients with High 
(>100nM/mmol) 
or Moderate (50-
99nM/mmol) 
levels of Ntx
Patients with Low 
(< 50nM/mmol) 
levels of Ntx
Stratify
Repeat measurement of Ntx2and radiographic 
assessment of response (repeat Q 3months)
Zoledronic Acid1IV Q 
4 weeks + Dasatinib 
PO (Dose established 
by Phase I portion of 
trial)
Repeat measurement of Ntx2
2 month 1 month
8 
 March 28, 2011
intolerability. 
Definition of Dose Limiting Toxicity 
Toxicity will be assessed using the NCI Common Toxicity Criteria (CTC) Scale, versi o
3.0.  
 By definition a DLT must occur during cycl e 1, be suspected as being drug-related, a
n
includes any of the following: 
 Any grade 4 non-hematological toxicity 
 Grade 4 neutropenia lasting > 7 da ys or any febrile neutropenia 
 Grade 3 non-hematological toxicity th at persists >72 hours despite adequa t
supportive care  
 Grade 2 or greater neutropenia (ANC<1.5x109/L) or thrombocytopen i
(PLT<75x109/L) which fails to revert to grade 1 (level at which treatment 
permitted) by the time of the scheduled start of cycle 2  
 50% decrease in calculat ed creatinine clearance 
 Diagnosis of osteonecrosis of the jaw 
Phase II Study Design 
 
The dose identified as the RP2D in the phase I portion of this study will be evaluated f o
efficacy in the phase II portion of  this trial. The primary objec tive of this phase II study is t
assess the efficacy (as defined by disease response) of dasatinib in combination wi t
zoledronic acid.  Patients wi ll be divided into two c ohorts dependant upon Ntx leve
obtained prior to the initiation of therapy. A ll patients will receive same therapy, lab dra w
and radiographic assessment for response.  
 Patients treated at the RP2D in the phase I portion of this study will be included in the 
efficacy analysis for the phase II portion of the trial. 
Up to 25 patients will be enrolled in this phase II study to assess the e fficacy of dasatinib i
n
combination with zometa (zoledronic acid).  The primary endpoint is the response rate.  T h
trial will be conducted by the Simon’s two-st age design using the minimax criterion and t h
response rate will be estimated accordingly [1]. 
 It is assumed that dasatinib in combination wi th zometa will have a ta rget response rate of 
25%.  A response rate of 5% or lower is considered a failure.  When the probability of 
accepting a “bad” regimen (i.e. response rate 5%) is 0.05 and the prob ability of rejecting 
“good” regimen (i.e. response rate  25%) is  0.10, Simon’s design to minimize the 
maximum sample size requires 15 patients in the first stage.  If no patients respond to the 
treatment, the trial will be stopped and the regimen will be declared as ineffective.  If at 
least one of the first 15 patients respond to the treatment, 10 additional patients will be entered in the study to reach a total of 25 patients.  By the end of the study, the new regim
e
will be rejected if response rate is less th an or equal to 3 out of 25 patients and will be 
9 
 March 28, 2011
accepted otherwise.  The operating characteristic s of the trial are given as follows.  When 
the true response rate is 0.05, the probability of stopping the trial earl y is 46.3%.  On the 
other hand, if the true response rate is 0.25, the probability to stop the trial early is 1.3%.  
The expected sample sizes are 20.37 and 24.97 when the true response rates are 0.05 and 
0.25, respectively.  At the end of the study, the response rate and the 95% confidence 
interval will be reported and the toxicity prof ile of the regimen will be summarized.  If the 
trial continues to the second stage (i.e., accrua l = 25) and the 5 of 25 patients response for a
point estimate of 20.0%, the exact binomial 95% confidence interval would be (6.8%, 
40.7%).   
 
 
Accrual Goal: 
(Total number of 
patients) 
  
6-28 patients 
6-18 patients may be enrolled in the phase I portion of the trial. In the phase II portion of the trial, 25 patients will be needed to establish efficacy. We will accrue an additional 10% of patients, a maxi mum of 28, to account for inevaluable patient
s
 
Accrual Rate: 
(Number of patients 
expected per month) 2-3 patients/month 
FPFV:  
LPLV: 
Follow Up: 
(dd-mm-yy) 11/06 11/10 Follow up will be completed on all patients by 11/30/11 
Trial Objectives: 
(Primary and 
Secondary) Primary Objectives:  
Phase I:  
To determine the maximum tolerated dose (MTD) and recommended phase II dose 
(RP2D) for dasatinib in combination with zoledronic acid. 
Phase II:  
Determine the efficacy of dasatinib in combination with zoledronic acid usi n
disease response. 
Secondary Objectives:  
Phase I:  
To determine toxicity of combination therapy with dasatinib and zoledronic acid in 
patients with breast cancer and bone metastasis.  
Phase II:  
 Changes in Ntx levels will be correlate d with traditional measurements of tum o
response in bone (using WHO criteria), progression free survival and over a
survival at 2 years  
 Biologic characterizatio n of response using 18F-FDG PET 
 Determination of molecular correlates of response in paraffin embedded or froz e
tissue  Determine time to tumor progression, response, time to tumor respons
10 
 March 28, 2011
progression free survival  (PFS) up to 2 years 
 Determine overall survival (OS) at 2 years 
 Banking of blood for future studies of novel markers of bone health 
 Determine changes in urinary Ntx with protocol therapy 
 Correlate response with tumo r estrogen receptor (ER), progesterone receptor (P R
and HER2 status 
 
Correlative 
Studies: 
 Biologic Characterization of Response Using 18F-FDG PET: 
Characterization of response using PET will be performed through collaboration with D
Juri Gelovani, chair of the De partment of Experimental Di agnostic Imaging in the Divisi o
of Diagnostic Imaging at MDACC. Patients who consent to participate will under g
optional 18F-FDG PET imaging at baseline, between days 12-16 of therapy (2 week valu e
and at disease progression.  The fold change fr om baseline will be calculated for the 2 we e
value and progression of disease value. These values will then be graphed using scatterplo
against urine Ntx to assess the relationship of response to this biologic endpoint.  I
addition, it is known that variations in 18F-FDG PET avidity can occur within different fo c
of disease in individual patients. These variations may represent biologic differenc e
between responding and non-responding cells; therefore, core needle biopsies will b
performed on a subset of patients who consent to biopsy of > 2 sites of metastatic tumo r
that differ in 18F-FDG PET uptake (see Molecular Correlates below).  
Determination of Molecular Correlates in Paraffin Embe dded or Frozen Tissue: 
Tumor biopsies will be obtained by imaging (CT or Ultrasound)  guided core needle biop s
from patients who sign informed consent for tissue biopsy. Biopsies will be obtained at pr e
treatment and at day 28 of cycle 1 (+/- 48 hours). Tumor samples will be analyzed f o
biomarkers of SRC, PDGFR, c-kit, FAK,  and EPHA2 total ki nase and phosphorylat e
activity, including Caveolin, Phospho-Caeo lin, IGFBP2 and pS TAT3 using standa r
immunohistochemistry techniques. Furthermor e, markers of angiogenesis VEGF and IL -
will also be analyzed using the same techniques. 
 Fresh tissue obtained by core needle biopsy of metastatic sites differing in PET avidity 
i
individual patients (see above ) will be snap frozen and used for microarray analysis t
determine potential pathways of drug resi stance. When possible, these results will b
confirmed using IHC, western blotting or PCR.  
Banking of Blood Samples: 
Patients will be asked to donate 10cc of bl ood pretreatment and on days 28 (+/- 48 hours) 
o
cycles 1 and 3. Blood will also be collected at the time of disease progression.  Serum w i
be banked for future treatment efficacy an alyses including potential markers of bo n
turnover.  
Inclusion 
Criteria: 1) Patients must have a pathologically conf irmed diagnosis of invasive carcinoma o
the breast.  
2) Patients must carry a diagnosis of metastatic breast cancer with predominant bo n
involvement. For the purposes of this study, predominant bone  involvement will b
11 
 March 28, 2011
defined as radiographically de tected bone metastasis in the presence or absence of oth e
sites of metastatic breast cancer (i.e. viscer al involvement). If visceral involvement 
present, patients must be asymptomatic and have no tumors in  visceral organs th a
measure >3cm in size.  
3) Patients must agree to serial urine collections for measurement of Ntx according t
the schedule defined in sections 8 and 9.  
4) Age > 18 years.  
5) Patients must be able to swallow oral medications. Dasatinib must be taken who l
and cannot be crushed.  
6) Patients must have evaluable disease us ing WHO Criteria for Assessment of Disea s
Response in Bone or the MDACC modified response criteria in bone (Post te x
supplement 4).  
7) Patients must not have >1  chemotherapy regimen for metastatic disease. Patie n
with metastasis diagnosed < 6 months after completion of adjuvant chemotherapy a r
considered to have had chemothera py for metastatic breast cancer.  
8) Patients with ER positive disease must ha ve had disease progre ssion on at least o n
prior hormonal therapy for metastatic disease.  Patients must also have developed disea s
progression on their most recent hormonal ther apy regimen and be agreeable to contin u
this regimen in combination with protocol therapy. For the purposes of this study disea s
progression while receiving hormonal therapy will be defined as:  
 Radiographic evidence of progressive  disease according to RECIST or WH O
criteria 
 Progression of disease by physical exam  in patients with skin involvement. 
 25% increase in tumor marker as measur ed on two evaluations no less than 72 hou r
apart.  
9) Patients must have and ECOG performance status of < 2.  
10) Patients must not require concurrent ra diation, or chemotherapy therapy whi l
receiving protocol therapy.  
11) Patients must not have an active inf ection requiring the use of intraveno u
antibiotics. The use of oral antibiotics as prophylaxis is allowed.  
12) Patients must have a baseline ECG with  QTc within the normal range within 2
days prior to registration.  
13) Patients must be informed of the inves tigational nature of the study and must si g
and give written informed consent.  
14) Patients may have received previous radiation but must have completed radiation a
least 2 weeks (8 weeks for radiation to th e brain) prior to re gistration. Patients wi t
irradiated tumor as the only site of evalua ble disease will not be eligible for protoc o
therapy unless there is documented disease pr ogression within the prev iously radiated sit e
15) Patients must have recovered to grade < 1 from all acute toxicity of previo u
radiation or hormonal therapy.  
16) Adequate hematologic and hepatic function: 
 Granulocyte count >  1,500/mcL  
 Platelet count >  100,000/mcL  
 Bilirubin <  1.5 x ULN  
12 
 March 28, 2011
 AST and/or ALT <  2 x ULN  
 Alkaline phosphatase (liver component, if fractionated) <  2 x ULN  
 Serum Na, K+, Mg2+, Phosphate and Ca2+Lower Limit of Normal (LLN) [subjec
with low electrolyte levels must be repleted to normal for protocol entry]  
17) Patients must not receive any concurre nt bisphosphonate therapy other than th a
prescribed by the study. 
18) Sexually active patients w ith reproductive potential must agree to use an effecti v
method of birth control during the course of  the study and for no less than 4 weeks aft e
discontinuing study drug. Contraceptives must  be used in a manner such that risk o
failure is minimized. Oral contraceptives s hould be avoided in women with estrogen o
progesterone receptor positive breast cancer.  
19) Prior to study enrollment, women of childbearing potential (WOCBP) must b
advised of the importance of avoiding pr egnancy during trial participation and t h
potential risk factors for an  unintentional pregnancy.  In addition, men enrolled on th
study should understand the risks to any sexu al partner of childbearing potential a n
should practice an effective method of birth control. 
20) All WOCBP MUST have a negative serum or urine pregnancy test within 72 hou r
prior to the start of study drug administration. If the pregnancy test is positive, the patie n
must not receive investigational product and must not be enrolled in the study. 
21) Patients with disease progression while re ceiving previous therapy in combinati o
with bisphosphonates (including zoledronic acid ) will be considered eligible for protoc o
participation.  
 
Exclusion 
Criteria:  
1) No malignancy (other than breast cancer) which required  radiotherapy or system i
treatment within the past 5 years.  
2) Concurrent medical condition which may in crease the risk of toxicity, including: 
 Pleural or pericardial effusion of any grade 
 Clinically-significan t coagulation or platelet f unction disorder (e.g. known v o
Willebrand’s disease) 
3) Cardiac Symptoms, including the following:  
 Uncontrolled angina, congestive heart failure or MI w ithin (6 months) 
 Diagnosed congenital long QT syndrome 
 Any history of clinically significant ventricular arrh ythmias (such as ventricul a
tachycardia, ventricular fibri llation, or Torsades de pointes) 
 Prolonged QTc interval on pre-entry electrocardiogram (> normal range) 
 Subjects with hypokalemia or hypomagne semia if it cannot be corrected 
4) History of significant bleeding disord er unrelated to cancer, including: 
 Diagnosed congenital bleeding disord ers (e.g., von Willebrand’s disease) 
 Diagnosed acquired bleeding disorder wi thin one year (e .g., acquired anti-fact o
VIII antibodies) 
13 
 March 28, 2011
 Ongoing or recent (  3 months) significant ga strointestinal bleeding 
5) Concomitant Medications, consider th e following prohibitions (Drugs must b
discontinued for 7 days prior to starting protocol therapy):  
 Drugs that are generally accepted to have a risk of causing Torsades de Point e
including:  
quinidine, procainamide, disopyramide, ami odarone, sotalol, ibutilide, dofetilide, 
erythromycins, clarithromycin, chlorp romazine, haloperidol, mesoridazine, 
thioridazine, pimozide, cisapride, be pridil, droperidol, methadone, arsenic, 
chloroquine, domperidone, halofantrine , levomethadyl, pentamidine, sparfloxacin, 
lidoflazine. 
 The concomitant use of H2 blockers or pr oton pump inhibitors with dasatinib is n o
recommended. The use of antacids should be considered in place of H2 blockers o
proton pump inhibitors in patient s receiving dasatinib therapy. 
 Patient agrees to discontinue St. Johns Wort while receiving dasatinib therapy  
 Patient may not be receiving any prohibited  CYP3A4 inhibitors [see section 7.6] 
6) Women and men of child bearing potential: 
 Who are unwilling or unable to use an acceptable method to avoid pregnancy for t h
entire study period and for at least 4 weeks after cessation of study drug, or 
 Women of childbearing poten tial (CBP) who have a positive pregnancy test a
baseline, or 
 Women who are pregnant or breastfeeding  
 Sexually active men and women capable of reproduction must use an effecti v
method of birth control during the c ourse of the study, in a manner such that risk o
failure is minimized 
 Prior to study enrollment, men and women capable of reproduction must be advis e
of the importance of avoiding pregnancy during trial participation and the potenti a
risk factors for an unintentional pregnancy   
7) Prisoners or subjects who are compulsorily detained (involuntarily incarcerated) f o
treatment of either a psychiatric or physical  (e.g., infectious) illness  
8) Untreated or uncontrolled brain metastasis  
9) Patient inability to take or absorb oral medications  
10) Current active dental problems including: ongoing infection of the teeth or jawbo n
(maxilla or mandibula); curr ent exposed bone in the mouth; and current or pri o
diagnosis of osteonecrosis of the jaw 
11) Recent (within 8 weeks) or planned dental  or jaw surgery (e.g., extraction, implant s
12) Diagnosis of metabolic bone disease othe r than osteoporosis (e.g., Paget’s disease o
bone)  
13) Known hypersensitivity to zoledronic acid or aspirin  
14) Corrected serum calcium  8.0 mg/dL (2.0 mmol/L) or  12.0 mg/dL (3.0 mmol/ L
at Visit 1.  The formula to  be used is:  Corrected serum calcium (mg/dL) = Patient
serum calcium (mg/dL) + [0.8 x Midrange Albumin (g/dL) – Patient’s Albumin (g/dL )
14 
 March 28, 2011
4.0g/dL to be used for the Midrange Albumin  
15) Serum creatinine 1.5 times the institutional upper limits of normal or a creatini n
clearance of <40 ml/min when calculate d by the Cockroft and Gault formula: 
Estimated creatinine clearance=  
(140-age in years) x (weight in kg)   (x 0.85, if female) 
72 x creatinine (mg/dL) 
 
Criteria for 
Evaluation: 
(Efficacy, safety, 
stopping rules, etc.) 
 For the phase 2 portion of the trial, a minimu m of  15 and a maximum of 28 patients will b
accrued.  Simon’s two stage design will be us ed to minimize the maximum sample size 
requires 15 patients in the first stage.  If no patients respond to the tr eatment, the trial will 
be stopped and the regimen will be declared as in effective.  If at leas t one of the first 15 
patients respond to the treatment, 10 additional patients will be entered in the study to reac h
a total of 25 patients.  
15 
 March 28, 2011
1 INTRODUCTION 
1.1 Hypothesis 
Dasatinib in combination with zoledronic acid will disrupt both the 
autocrine and paracrine loops that su stain breast cancer metastasis within 
the bone. This therapeutic effect will result in a significant reduction of N-telopeptide of Type I Collagen (Ntx),  a marker of bone resorption, which 
will correlate with clinical outcomes of tumor response, time to progression and overall survival. 
1.2 Background 
1.2.1 
1.2.2 Bone Metastasis in  Patients with Breast 
Cancer 
Up to 70% of patients w ith advanced breast cancer develop metastasis to 
the bone and, although bone metastasis is associated with a favorable 
prognosis, a median survival of 9 m onths has been published in patients 
with progressive bony metastasis or  hormone refractory breast cancer (1, 
2). Many of these patients are also ineligible for most clinical trials 
because of the complexities involved in measuring the therapeutic response of lesions within the bone(3).  Skeletal related events (SREs) resulting from bone metastasis are al so the source of a significant amount 
of morbidity, which may necessitate  additional medical or surgical 
intervention.   Metastasis to the bone initiates a vici ous cycle where the metastatic cells 
stimulate osteoclast mediated bone re sorption and growth factors released 
from resorbed bone promote tumor growth  (1). Src has been implicated in 
the autocrine and paracr ine interactions invol ved in promoting bone 
metastasis and is thus a potential target for the treatment of breast cancer that has metastasized to the bone. 
The Role of Src in Breast Cancer 
Src kinase modulates oncogenic si gnal transduction through multiple 
pathways such as EGFR, HER 2, PDGFR, FGFR and VEGFR. 
Approximately 50-65% of human br east carcinomas overexpress c-Src 
and up to 85% of human breast carcinomas have detectable levels of activated Src (Src-pY
416)(4-6). Src signaling is significantly activated in 
breast tumors compared with normal breast tissue and has been correlated with chemotherapy resistance and antia poptotic signaling in both cell lines 
and clinical trials involving breast cancer patients (7, 8). Elevated Src 
tyrosine kinase activity has also been  associated with poor metastasis-free 
survival in breast cancer patients and with tumor colonization in bone and 
lung in animal models of human breas t cancer metastasis(9). In these 
16 
 March 28, 2011
models, activation of Sr c was associated with increased tumor cell 
production of PTH-rP, a powerful stimulat or of osteoclast  bone resorption 
that has been shown to play an im portant role in osteolytic bone 
metastasis. 
1.2.3 
1.2.4 The Role of Src in the Regulation of 
Osteoclast Function 
Osteoclasts are multinucleated giant cel ls which contain ruffled borders or 
polarized portions of cell membra ne where bone resorption occurs. 
Osteoclasts express high levels of Src which is involved with 
osteoclastogenesis, cytoskeletal or ganization and formation of ruffled 
boarders [reviewed in (10)]. Expre ssion of c-Src in  osteoclasts is 
controlled by NF- B and AP-1 and disruption of this pathway using 
antisense src or c- src knock-out mice results in perturbations in the 
formation of multinucleated cells and morphologically abnormal cells with 
aberrant cytoskeletal organizatio n and absence of ruffled borders 
[reviewed in (10)]. Disruption of Src with small molecular weight tyrosine 
kinase inhibitors (TKIs) has also be en demonstrated to dose-dependently 
reduce interleukin-  induced hypercalcemia in mice and partially 
prevented bone loss in young ovariectomized rats(11). 
The Role of PDGF in Bone Metastasis 
Breast cancer specimens evaluated by immunohistochemistry (IHC) show 
expression of PDGF in the cancer ce lls and associated expression of 
PDGFRs predominately within the st roma, including vascular endothelial 
cells in the periepithelial stroma [rev iewed in (12)]. In addition, inhibition 
of PDGF by neutralizing antibody, tran sfection with antis ense vector or 
treatment with tyrosine kinase inhib itors (TKIs) has be en shown to block 
cancer induced osteoblastic bone fo rmation, reduce bone metastasis and 
inhibit growth of established meta stasis in breast cancer xenograft 
models(12, 13). 
 
 
2 OVERVIEW OF STUDY DRUGS 
2.1 Dasatinib 
Dasatinib [SPRYCEL®] is a poten t, broad spectrum ATP-competitive 
inhibitor of 5 critical oncogenic ty rosine kinase/kinase families: BCR-
ABL, SRC, c-KIT, PDGF receptor β (PDGFRβ ), and ephrin (EPH) 
receptor kinases, each of which has been linked to multiple forms of 
human malignancies(14).  
Drug discovery and nonclinical pharmacology studies showed that 
Dasatinib(15):  
17 
 March 28, 2011
 Kills BCR-ABL dependent leukemic cell lines, including a number 
that are resistant to imatinib due  to kinase domain mutations or 
overexpression of SRC family kinase s and is effective against all 
imatinib-resistant kinase domain mu tations tested to date, except 
T315I 
 Inhibited proliferation of cancer cell lines that express activated 
SRC or  c-KIT 
 Potently inhibits VEGF-stimulated proliferation and migration in 
HUVECs 
 Has potent bone anti-resorptive activity  
 
2.1.1 Preclinical Anti-tumor Activity 
2.1.1.1 In Vitro Molecular Studies 
Dasatinib potently inhibits: SRC kinases, BCR-ABL, c-KIT, PDGFRβ  and 
EPHA and was less potent against 16 other unrelated protein tyrosine 
kinases (PTKs) and serine/threonine kinases. Imatinib is less potent 
against several key enzymes: for ex ample, Dasatinib was 260-, 8-, 60-, 
and >1000-fold more potent than imatinib versus BCR-ABL, c-KIT, 
PDGFR, and SRC kinases, respectively(15).   
In vitro , dasatinib was active in leukemic cell lines representing variants of 
imatinib mesylate sensitive and resistant disease. dasatinib inhibited the 
growth of chronic my eloid leukemia (CML) and acute lymphoblastic 
leukemia (ALL) cell lines overexpr essing BCR-ABL. Under the 
conditions of the assays, dasatinib was able to overcome imatinib resistance resulting from BCR-ABL ki nase domain mutations, activation 
of alternate signaling pathways invo lving the SRC family kinases (LYN, 
HCK), and multi-drug resistance gene overexpression(14).  
Dasatinib inhibits the BCR-ABL kinase with an in vitro  IC
50 of 3 nM, a 
potency 260-fold greater than that of imatinib mesylate (IC 50 = 790 nM). 
In cellular assays, dasatinib killed or  inhibited the proliferation of all 
BCR-ABL dependent leukemic cell lines tested to date. Dasatinib also 
demonstrated undiminished anti-tumor activity against several 
preclinically- and clinically-derived  models of imatinib mesylate 
resistance. Evidence that SRC family kinase over expression may play a role in clinical resistance to imatin ib mesylate was demonstrated in three 
CML cell lines established from patients who failed imatinib mesylate therapy. These cells remained highly sensitive to the cell-killing effects of dasatinib(15).  
These results demonstrate that dasatinib is effective in reducing the 
proliferation or survival of both ima tinib mesylate-sensitive and resistant 
cells, and its inhibitory activity is  not solely dependent on BCR-ABL. 
18 
 March 28, 2011
2.1.1.2 In Vivo Studies 
The activity of dasatinib against CML cells in vitro  was reproduced in vivo  
against several human CML xenograft models grown subcutaneously in 
SCID mice. Against the K562/imatinib  mesylate/R CML model, Dasatinib 
was curative in 100% of the treated an imals. In contrast, at its optimal 
dose and schedule, imatinib mesylate was inactive. 
2.1.
2.1.2 Preclinical Toxicology 
Single or repeated oral administration of dasatinib principally affected the 
gastro-intestinal (GI) tract, includi ng the liver, the hematopoietic, and 
lymphoid systems in rats and monkeys. Other prominent effects after 
single oral administration of dasatinib included renal and cardiac toxicity in rats at lethal doses, and cutaneous hemorrhage in monkeys. Dasatinib can also affect the immune  system and bone turnover. 
Dasatinib in vitro  activity in the HERG/IKr and Purkinje-fiber assays 
indicated a moderate liability fo r prolongation of cardiac ventricular 
repolarization (QT interval) in the clinic. However, there were no dasatinib -related changes observed in  electrocardiograms, nervous system 
function, respirations and heart rate, blood pressu re, or arterial oxygen 
saturation in single-dose, 10-day, or 1-month oral toxicity studies in monkeys. 
Dasatinib was found to exhibit a pr ofile of broad-sp ectrum platelet 
inhibition best typified by anti-platelet agents such as the GPIIb/IIIa 
antagonists, integrelin and abciximab. 
Finally, modulation of SRC kinase activ ity could also affect osteoclast 
morphology and function and bone remodeling. This effect could 
potentially result in an increase in bone mineral density and a phenotype 
analogous to osteopetrosis(15).  
3 Clinical Pharmacokinetics 
The pharmacokinetics of dasatinib ha ve been evaluate d in 229 healthy 
subjects and in 137 patients with leukemia.  
2.1.3.1 Absorption 
Maximum plasma concentrations (C
max) of dasatinib are observed 
between 0.5 and 6 hours (T max) following oral administration. dasatinib 
exhibits dose proportional increases in AUC and linear elimination 
characteristics over the dose range of  15 mg to 240 mg/day. The overall 
mean terminal half-life of dasatinib is 3–5 hours(14).  
Data from a study of 54 healthy subjects administered a single, 100-mg dose of Dasatinib 30 minutes following consumption of a high-fat meal resulted in a 14% increase in the mean AUC of dasatinib. The observed 
food effects were not clinically relevant.  
19 
 March 28, 2011
2.1.3.2 Distribution 
In patients, dasatinib has an appare nt volume of distribution of 2505 L, 
suggesting that the drug is extensively distributed in the extravascular 
space. Binding of dasatinib and its active metabolite to human plasma 
proteins in vitro  was approximately 96% and 93%, respectively, with no 
concentration dependence over the range of 100–500 ng/mL(14).   
2.1.3.3 Metabolism 
Dasatinib is extensively metaboli zed in humans, primarily by the 
cytochrome P450 enzyme 3A4 (see section 7.6).  CYP3A4 was the primary enzyme responsible for the formation of the active metabolite. 
Flavin-containing monooxygenase 3 (F MO-3) and uridine diphosphate-
glucuronosyltransferase (UGT) enzymes are also involved in the formation of dasatinib metabolites.  In human liver microsomes, dasatinib 
was a weak time-dependent inhibitor of CYP3A4.   
The exposure of the active metabolite, which is equipotent to dasatinib, 
represents approximately 5% of the da satinib AUC.  This indicates that the 
active metabolite of dasatinib is unlikely to play a major role in the 
observed pharmacology of the drug.  dasatinib also had several other 
inactive oxidative metabolites.  
2.1.3.4 Elimination 
Elimination is primarily via the f eces. Following a single oral dose of 
[
14C]-labeled dasatinib, approximately  4% and 85% of the administered 
radioactivity was recovered in the urine and feces, respectively, within 10 days. Unchanged dasatinib accounted for 0.1% and 19% of the administered dose in urine and feces, respectively, with the remainder of the dose being metabolites(14).  
2.1.4 Clinical Experience with Dasatinib 
Four single-arm multicenter studies were conducted to determine the 
efficacy and safety of dasatinib in patients with CML or Philadelphia 
chromosome-positive acute lymphoblas tic leukemia (Ph+ ALL) resistant 
to or intolerant of treatment with imatinib. Resistance to imatinib included failure to achieve a complete hematologic response (within 3–6 months) or major cytogenetic response (by month 12)  or progression of disease after a 
previous cytogenetic or hematologic response. Imatinib intolerance included inability to tolerate 400 mg  or more of imatinib per day or 
discontinuation of imatinib because of toxicity. The studies are ongoing. The results are based on a minimum of 6 months follow-up after the start 
of DASATINIB therapy. Most patients had long disease histories with 
extensive prior treatment, including  imatinib, cytotoxic chemotherapy, 
interferon, and stem cell transplant. The maximum imatinib dose had been 
20 
 March 28, 2011
400–600 mg/day in about one-half of the patients and >600 mg/day in the 
other half(14).  
All patients were treated with dasa tinib 70 mg BID on a continuous basis. 
The median durations of treatmen t was between 2.8 - 5.6 months(14).  
The primary efficacy endpoint in chronic phase CML was major 
cytogenetic response (MCyR), defi ned as elimination (complete 
cytogenetic response, CCyR) or substa ntial diminution (by at least 65%, 
partial cytogenetic resp onse) of Ph+ hematopoietic cells. The primary 
endpoint in accelerated phase, myeloi d blast phase, and lymphoid blast 
phase CML, and Ph+ ALL was major hematologic response (MaHR), defined as either a complete hematologic response or no evidence of leukemia as defined in Table 3. 
Most cytogenetic responses occurred  after 12 weeks of treatment, when 
the first cytogenetic analyses we re performed. Hematologic and 
cytogenetic responses were stable during the 6-month follow-up of 
patients with chronic phase, accelerated phase, and myeloid blast phase CML. The median durations of ma jor hematologic response were 3.7 
months in lymphoid blast CML a nd 4.8 months in Ph+ ALL.   
There were no age- or gender-re lated response differences(14).  
21 
 March 28, 2011
Table 3: Efficacy in Dasatinib Clinical Studies (All Treated 
Populations)a 
 Chronic 
(n=186) Accelerated 
(n=107) Myeloid 
Blast 
(n=74) Lymphoid 
Blast 
(n=42) Ph+  ALL 
(n=36) 
Hematologic Response Rateb (%) 
MaHR (95% CI) n/a 59 (49–68) 32 (22–44) 31 (18–47) 42 (26–59) 
 CHR (95% CI) 90 (85–94) 33 (24–42) 24 (15–36) 26 (14-42) 31 (16–48) 
 NEL (95% CI) n/a 26 (18–36) 8 (3–17) 5 (0.6–16) 11 (3.1–26) 
Cytogenetic Responsec (%) 
MCyR (95% CI) 45 (37–52) 31 (22–41) 30 (20–42) 50 (34–66) 58 (41–74) 
 CCyR (95% CI) 33 (26–40) 21 (14–30) 27 (17–39) 43 (28–59) 58 (41–74) 
a 
Numbers in bold font are the results of primary endpoint. 
b Hematologic response criteria (all responses confirmed after 4 weeks): 
 Major hematologic response: (MaHR) = complete hematol ogic response (CHR) + no evidence of leukemia (NEL).  
CHR (chronic CML): WBC  institutional ULN, platelets <450,000/mm3, no blasts or promyelocytes in peripheral blood, 
<5% myelocytes plus metamyelocytes in pe ripheral blood, basophils in peripheral blood  institutional ULN, and no 
extramedullary involvement. 
CHR (advanced CML/Ph+ ALL):  WBC  institutional ULN, ANC 1000/mm3, platelets ≥100,000/mm3, no blasts or 
promyelocytes in peripheral blood, bone marrow blasts 5%, <5% myelocytes plus metamyelocytes in peripheral blood, 
basophils in peripheral blood  institutional ULN, and no extramedullary involvement. 
NEL: same criteria as for CHR but ANC 500/mm3 and <1000/mm3, and/or platelets 20,000/mm3 and 100,000/mm3. 
c Cytogenetic response criteria: complete (0% Ph+ metaphase s) or partial (>0%–35%). MCyR (0%–35%) combines both 
complete and partial responses. 
n/a = not applicable. 
 
2.1.5 Safet y of Dasatin ib in Clinical Studies 
The data described below reflect exposur e to dasatinib in 911 patients with 
leukemia from 1 Phase I and 5 Phase II clinical studies. The median 
duration of therapy was 6 months (range 0–19 months).  
The majority of dasatinib -treated  patients experienced adverse drug 
reactions at some time. Drug was di scontinued for adverse drug reactions 
in 6% of patients in chronic phase CML, 5% in accelerated phase CML, 
11% in myeloid blast phase CML, and 6% in lymphoid blast phase CML 
or Ph+ ALL.  
The most frequently reported seriou s adverse events (SAEs) included 
pyrexia (9%), pleural effusion (8 %), febrile neutropenia (7%), 
gastrointestinal bleeding (6%), pne umonia (6%), thrombocytopenia (5%), 
dyspnea (4%), anemia (3%), cardiac fa ilure (3%), and diarrhea (2%).   
All treatment-emergent adverse events (excluding laboratory 
abnormalities), regardless of relationship  to study drug, that were reported 
in at least 20% of the patients in da satinib clinical studies are shown in 
Table 4. 
22 
 March 28, 2011
Table 4: Adverse Events Reported ≥20% in Clinical Studies 
All Patients 
(n=911) Chronic 
Phase 
(n=488) Accelerated 
Phase 
(n=186) Myeloid 
Blast 
Phase 
(n=132) Lymphoid 
Blast Phase 
and 
Ph+ ALL 
(n=105) 
All 
Grades Grades 
3/4 Grades 3/4 Grades 3/4Grades 
3/4 Grades 3/4 
Preferred Term Percent (%) of Patients 
Fluid Retention 50 9 6 6 23 9 
 Superficial Edema 36 1 0 2 3 2 
 Pleural Effusion 22 5 3 3 14 8 
Diarrhea 49 5 3 10 8 6 
Headache 40 2 2 2 4 6 
Hemorrhage 40 10 3 18 23 17 
Musculoskeletal Pain 39 4 2 3 6 13 
Pyrexia 39 5 1 5 13 9 
Fatigue 39 3 2 4 4 8 
Skin Rash  a35 1 1 1 1 4 
Nausea 34 
1 <1 0 5 2 
Dyspnea 32 6 5 7 11 9 
Cough 28 <1 <1 1 1 0 
Infection (including bacterial, 
viral, fungal, non-specified) 34 7 4 8 15 13 
 Infection/Inflammation 26 1 1 1 5 1 
Abdominal Pain 25 2 1 2 4 6 
Pain 26 2 <1 1 5 4 
Vomiting 22 1 1 2 2 2 
Febrile Neutropenia 9 8 2 11 17 20 
23 
 March 28, 2011
2.1.6 Laboratory Abnormalities 
Myelosuppression was commonly reported in all patient populations. The 
frequency of Grade 3 or 4 neutropeni a, thrombocytopenia, and anemia was 
higher in patients with advanced CML or Ph+ ALL than in chronic phase 
CML. Myelosuppression was reported in patients with  normal baseline 
laboratory values as well as in pa tients with pre-existing laboratory 
abnormalities.  (Table 5) 
In patients who experienced severe  myelosuppression, recovery generally 
occurred following dose interruption and/or reduction; permanent 
discontinuation of treatment occurred in 1% of patients.  
Grade 3 or 4 elevations of transaminases or bilirubin and Grade 3 or 4 hypocalcemia and hypophosphatemia were re ported in pati ents with all 
phases of CML but were reported with an increased frequency in patients 
with myeloid or lymphoid blast CML and Ph+ ALL. Elevations in transaminases or bilirubin were us ually managed with dose reduction or 
interruption.  Patients developing Grade 3 or 4 hypocalcemia during the 
course of dasatinib therapy often had recovery with oral calcium 
supplementation.  (Table 5). 
 
Table 5: CTC Grades 3/4 Laboratory Abnormalities in Clinical 
Studies 
 
Chronic Phase
(n=488) Accelerated 
Phase 
(n=186) Myeloid Blast 
Phase 
(n=132) Lymphoid Blast 
Phase and 
Ph+ ALL 
(n=105) 
 Percent (%) of Patients 
Hematology Parameters     
 Neutropenia 49 74 83 81 
 Thrombocytopenia 48 83 82 83 
 Anemia 18 70 70 51 
Biochemistry Parameters     
 Hypophosphatemia 11 13 23 21 
 Hypocalcemia 2 9 20 15 
 Elevated SGPT (ALT) 1 4 7 11 
 Elevated SGOT (AST) 1 2 5 8 
 Elevated Bilirubin <1 1 5 8 
 Elevated Creatinine 0 2 1 1 
CTC grades: neutropenia (Grade 3 ≥0.5–1.0 × 109/L, Grade 4 <0.5 × 109/L); thrombocytopenia (Grade 3 ≥10–50 
× 109/L, Grade 4 <10 × 109/L); anemia (hemoglobin ≥65–80 g/L, Grade 4 <65 g/L); elevated creatinine (Grade 3 
>3–6 × upper limit normal range (ULN), Grade 4 >6 × ULN); elevated bilirubin (Grade 3 >3–10 × ULN, Grade 
4 >10 × ULN); elevated SGOT or SGPT (Grade 3 > 5–20 × ULN, Grade 4 >20 × ULN); hypocalcemia (Grade 3 
<7.0–6.0 mg/dL, Grade 4 <6.0 mg/dL); hypophosphatemia (Grade 3 <2.0–1.0 mg/dL, Grade 4 <1.0 mg/dL).  
24 
 March 28, 2011
 
2.1.7 Anticipated Adverse Events 
Myelosuppression  
Treatment with dasatinib B is associated with severe (NCI CTC Grade 3 
or 4) thrombocytopenia, neutropeni a, and anemia. Their occurrence is 
more frequent in patients with advanced CML or Ph+ ALL than in chronic phase CML. Complete blood counts s hould be performed weekly for the 
first 2 months and then monthly therea fter, or as clinically indicated. 
Myelosuppression was generally reve rsible and usually managed by 
withholding dasatinib tempor arily or dose reduction(14).   
Bleeding Related Events 
In addition to causing thrombocytope nia in human subjects, dasatinib 
caused platelet dysfunction in vitro . Severe CNS hemorrhages, including 
fatalities, occurred in 1% of patients receiving dasatinib. Severe 
gastrointestinal hemorrhage occurred in 7% of patients and generally 
required treatment interruptions and tr ansfusions. Other cases of severe 
hemorrhage occurred in 4% of patie nts. Most bleeding events were 
associated with severe thrombocytopenia.  
Patients were excluded from participation in dasatinib clinical studies if 
they took medications that inhibit platelet function or anticoagulants. 
Caution should be exercised if patients are required to take medications that inhibit platelet f unction or anticoagulants.  
Fluid Retention 
Dasatinib is associated with fluid retention, which was severe in 9% of 
patients, including pleural and pericard ial effusion reported in 5% and 1% 
of patients, respectively. Severe ascites and generalized edema were each 
reported in 1%. Severe pulmonary edem a was reported in 1% of patients. 
Patients who develop symptoms sugges tive of pleural effusion such as 
dyspnea or dry cough should be evaluate d by chest X-ray.  Severe pleural 
effusion may require thoracentesis and oxygen therapy.  Fluid retention 
events were typically managed by s upportive care measures that include 
diuretics or short cour ses of steroids(14). 
 
25 
 March 28, 2011
QT Prolongation 
In vitro  data suggest that dasatinib has the poten tial to prolong cardiac 
ventricular repolarization (QT interval). In single-arm clinical studies in 
patients with leukemia treated with dasatinib, the mean QTc interval changes from baseline using Fridericia’s method (QTcF) were 3–6 msec; the upper 95% confidence intervals for all mean changes from baseline were <8 msec. Nine patients had QT c prolongation reported as an adverse 
event.  Three patients (<1%) experienced a QTcF >500 msec.  
Dasatinib should be administered w ith caution to patie nts who have or 
may develop prolongation of QTc.
 These include patients with 
hypokalemia or hypomagnesemia, patie nts with congenital long QT 
syndrome, patients taking anti-arrhythm ic medicines or other medicinal 
products that lead to QT prol ongation, and cumulative high-dose 
anthracycline therapy.  Hypokalemia or hypomagnesemia should be 
corrected prior to dasatinib administration(14).  
2.1.8 Phase I experience in Solid Tumors 
In a Phase I study (CA180003) conducted by Bristol Myers Squibb 
(BMS), dasatinib was administered on  a BID schedule to 42 subjects with 
refractory solid tumor. To date, doses  up to 160 mg BID on a 5-day on/2-
day off schedule have been administered. A dose of 120 mg BID 
continuous daily schedule is currently under investigation.  
No severe clinical toxicity has been encountered. Gastrointestinal 
symptoms were reported in most s ubjects, fatigue wa s reported in 17 
subjects (40%) and rash in 10 s ubjects (24%). Edema, lethargy and 
headache were uncommon, and appear to be dose-related. Grade 3 asymptomatic hypocalcemia was considered dose-limiting in one subject, 
Grade 2 rash was considered dose-limiting in two other subjects, and 
Grade 2 nausea and vomiting (with dysarthria, lightheadedness and 
lethargy in a 49 kg subject taking concurrent diazepam) was considered dose-limiting in one subject.   
In another Phase I study (CA180021), da satinib was administered on a QD 
schedule to 24 subjects at doses up to 180 mg. Pleural effusions were 
observed in three subjects at the 180  mg dose level (one with pneumonia 
and two with malignant effusion). A dose of 250 mg QD is currently under 
consideration. Hypocalcemia, GI symptoms and skin rash have been mild 
and infrequent.   
To date, the safety profile in solid tu mor subjects has been similar to that 
in CP CML subjects with the exception of severe myelosuppression, 
26 
 March 28, 2011
which has not been observed in solid  tumor subjects and is considered 
related to efficacy against the leukemia as noted above, and severe 
bleeding which is secondary to th rombocytopenia in most instances.  
2.2 Zoledronic Acid 
The principle pharmacologic action of zoledronic acid is inhibition of 
bone resorption.  Although the antiresorp tive mechanism is not completely 
understood, several factors are thought  to contribute to this action.  In 
vitro , Zoledronic acid inhibits osteoclastic activity and induces osteoclast 
apoptosis.  Zoledronic acid also blocks  the osteoclastic  resorption of 
mineralized bone and cartilage thro ugh its binding to bone.  Zoledronic 
acid inhibits the increased osteoclastic activity and skeletal calcium 
release induced by various stimulator y factors released by tumors.   
Zoledronic acid has demonstrated efficacy and safety in phase II and phase III clinical tria ls(16). The phase II study was a randomized, double-
blind study of 280 patients with malignant bone lesions associated with multiple myeloma or breast cancer(16). Patients were randomized to a 5-minute infusion of 0.4, 2.0, or 4.0 mg of zoledronic acid, or a 2-hour 
infusion of 90 mg of pamidronate. Adve rse events with zoledronic acid 
and pamidronate were similar, and the 5-minute 4.0-mg zoledronic acid 
infusion was equally efficacious wh en compared to a 2-hour 90-mg 
pamidronate infusion.  
Zoledronic acid has been evaluated in three prospective, randomized, 
controlled studies.  [Study 0010] was a randomized, double-blind, double-
dummy, 12-month study of 1,122 patients with at least on e osteolytic bone 
lesion secondary to multiple myeloma or at least one bone metastasis 
secondary to Stage IV breast carcin oma(17). Patients were randomized to 
15-minute 4-mg infusions of zoledr onic acid, or to 120-minute 90-mg 
infusions of pamidronate, while receivi ng standard antineoplastic therapy.  
Analysis of the primary endpoint revealed  that zoledronic acid was at least 
as effective as pamidronate at re ducing skeletal related events.  
Tolerability was similar for the tw o drugs, with bone pain, nausea, and 
fatigue the most common adverse events. There was no significant 
difference between the renal safety  profiles for zoledronic acid and 
pamidronate after renal safety amendments for zoledronic acid were implemented.  
Two additional phase III studies demonstrated the safety and efficacy of 
zoledronic acid in patients with bone metastases associated with prostate cancer, and non-small cell lung cancer or other solid tumors.  Saad, et al. reported a phase III, double-blind, placebo-controlled study that enrolled 422 patients with prostate cancer receiving antineoplastic therapy, and 
who had metastatic bone lesions and three consecutive rises in serum PSA 
level(18). In this study, zoledronic ac id reduced the proportion of patients 
with SREs during the study by 25%, when compared with placebo.  
27 
 March 28, 2011
Rosen, et al. published a phase III d ouble-blind, placebo-controlled study 
in 507 patients with malignancies other than breast, prostate, or multiple 
myeloma, and documented bone metast ases(19). This study demonstrated 
that treatment with zoledronic acid i nduced a significant delay to the first 
SRE and a significant reduction in the risk of developing SRE, compared 
to placebo. Both studies confirmed the safety profile of zoledronic acid.  
 For details regarding drug prepar ation mechanism of action and 
prescribing information please see s ection 10.7 and Post-text supplement 2 
[Package Insert for Zometa (Zoledronic acid)]. 
 
3 STUDY RATIONALE 
3.1 Rationale for the Use of Dasatinib in 
Combination with Zoledronic Acid for the Treatment 
of Hormone Receptor Negative Metastatic Breast 
Cancer and in Combination with Antiestrogen Therapy in Patients with Hormone Receptor Positive 
Breast Cancer 
Dasatinib is a novel, broad spectrum ATP competitive inhibitor of tyrosine 
kinases such as BCR-ABL, Src, c-KIT,  PDGFR and ephrin (EPH). Src has 
been implicated as a ta rget in both hormone receptor positive and triple 
negative breast cancer cell lines. In estrogen receptor (ER) positive cell 
lines, inhibition of ER/Src interaction leads to inactivation of the Src/Erk pathway, reduction in cyclin D1 ex pression and DNA synthesis induced 
by estradiol.(20) Disruption of the ER/Src association also leads to 
inhibited tumor growth in MCF-7 xenografts.(20) Additionally, PGC-1 
beta (a strong enhancer of ER  activity) and SRC-1 have been 
demonstrated to functionally interact  and promote the agonist activity of 
tamoxifen. Inhibition of the ER/Src association through peptide mimetics 
or Src inhibitors results in dimini shed growth in br east cancer xenograft 
models and restores sensitivity to anti-estrogen therapy in these same models.(20, 21) Preclinical data have  demonstrated cytotoxic activity 
against the breast cance r cell line MDA-MB-231 a nd complete inhibition 
of PTH-stimulated bone  resorption in thyro- parathyroidectomized 
rats(15).   Zoledronic acid has been evaluated in three randomized double blind trials 
which demonstrated reductions in the ri sk of skeletal events of 27-36% in 
patients with prostate cancer, non-sm all cell lung cancer and other solid 
tumors(22-24) . In breast cancer, zoledronic acid was compared to pamidronate and demonstrated an additional 20% reduction in skeletal events (25).
 Zoledronic acid is a nitrogen c ontaining bisphosphonate that 
inhibits osteoclast mediated bone re sorption by blocking FFP synthase and 
28 
 March 28, 2011
subsequent prenylation of GTPases that  regulate osteoclast cytoskeletal 
organization (26). As mentioned in section 1.2.3 , Src is also important in 
regulating the cytoskeletal organiza tion necessary for formation of the 
ruffled boarder where bone resorption occurs. As such, both agents may 
offer an additive effect in combination for the prevention of bone 
resorption and improvement in  skeletal related events. 
  In addition, preclinical data indicate that zoledronic acid sensitizes endothelial cells to tumor necrosis factor (TNF) programmed cell death by 
inhibiting focal adhesion kinase  (FAK) and protein kinase B 
(PKB/Akt)(27). These effects were i ndependent of c-Src activation and 
suggest that treatment with zo ledronic acid may augment the anti-
angiogenic effects previously described with dasatinib.  
    Taken together, these data support a potential therapeutic role for the 
combined use of dasatinib with zoledronic acid to inhibit osteolytic bone destruction and the subsequent releas e of growth factors that support 
cancer cell prolifera tion and survival. 
 
3.2 Rationale for Evaluating Therapeutic Response 
in Bone and Correlating N-telopeptide of Type I 
Collagen (Ntx) with Therapeutic Response 
Traditional assessment of bone tumo r response using imaging studies 
remains challenging and often limits patients with bone only metastasis 
from participating in clinical trials. In addition, traditional imaging studies 
such as bone scan or plain films us ed by the World Health Organization 
(WHO) criteria for response in bone  were published in 1977 and show 
only moderate sensitivity when assessing for response, may lead to false diagnoses of tumor progression (flare phenomenon), or take months to show response because they measure skeletal architecture changes that 
occur slowly over time. These guide lines also were not adopted by 
RECIST or RECIST 1.1, creating a voi d regarding the evaluation of bone 
metastases. This void lead to the development of bone-specific response criteria at the M. D. Anderson Ca ncer Center in 2004.(45) The MDA 
criteria revised the evaluation of bon e metastases previously adopted by 
UICC and WHO by modify ing radiographic assessment and updating the 
technology to include both CT and MRI.   The MDA criteria divide response into  4 standard categories (CR, PR, PD 
and SD, see post-text supplement 4) and include quantitative and 
qualitative assessments of the behavi or of bone metastases. Quantitatively, 
the MDA criteria adopted the method of physical measurement put forth by the UICC and WHO criteria which defi ne PR as a decrease of 50% or 
more in the sum of the perpendicular measurements of a lesion and PD as 
a reduction of 25% or more in this sum. 
29 
 March 28, 2011
 
Using the MDA criteria, complete response is defined as complete sclerotic fill-in of lytic lesions on ra diographs (XR) or CT; the restoration 
of normal bone density at the site of  a blastic lesion on XR or CT; the 
disappearance of abnormal tracer uptake on skeletal scintigraphy (SS); and normalization of signal intensity on MRI. The PR category includes the 
development of a sclerotic rim or par tial (rather than complete) sclerotic 
fill-in of lytic metastases on XR or CT, >
 50% decrease in measurable 
lesions on XR, CT or MRI (Fig. 7), s ubjective unequivocal decrease in the 
size of blastic lesions on XR or CT that cannot be accounted for by 
changes in obliquity or slice placement and unequivocal decrease in tracer uptake on SS. A caveat to the PR designation involves osteosclerotic “flare.” Interval visualiz ation of sclerotic lesions or lytic lesions with 
sclerotic rims, in the setting of other signs of PR, does not  indicate disease 
progression but the healing of previ ously inconspicuous lesions. The 
caveat does not apply if any pre-exis ting lesions show si gns of progression 
(e.g. enlargement of lytic lesions, development of new lytic lesions). The PD category includes a >
 25% increase in the size of any measurable 
lesion on XR, CT or MRI; unequivo cal increase in the size of 
unmeasurable (ill-defined) lytic or bl astic lesions that cannot be accounted 
for by obliquity or slice placement, unequivocal increase in tracer uptake on SS; or the development of new meta stases. Flare occurs when healing 
sclerosis results in more tracer upt ake than was caused by the untreated 
lesion. Correlation of SS with another imaging modality is also suggested 
for the rapid resolution of tracer uptake in pre-existing lesions. Rarely, this is due to the rapid progression of lytic metastases. When lytic lesions 
progress quickly, the bone is unabl e to produce reparative sclerosis, 
rendering tracers such as methylene diphosphate (MDP) ineffective 
because they normally bind to the crys talline phase of hydroxyapetite laid 
down by the bone as it attempts to heal the damage caused by the lesion. In this unusual situation, the rapi dly progressing metast ases destroy pre-
existing skeletal tissue that demonstrat ed tracer uptake. SD is defined as < 
25% increase, < 50 % increase in meas urable lesions or no change and no 
new lesions.  Upon comparison of the MDA, UICC and WHO criteria in a study of 41 
breast cancer patients with bone-onl y metastases, MDA was shown to 
better differentiate responders from  non-responders and was the only set 
of criteria to correspond to progre ssion-free survival. Using the MDA 
criteria, time to disease progressi on was found to be 5.5 months for non-
responders and 23.3 months for respo nders (p = 0.025) while it was 10.4 
months and 12.4 months respectively,  using the WHO criteria (p = 0.55). 
MDA identified non-responders earl ier and was also found to better 
correlate with clinical response in the first 2-6 months of therapy in 
comparison to the WHO criteria. Early signs of disease progression are valuable, allowing ineffective therapy to  be halted in a timely fashion and 
30 
 March 28, 2011
the possible substitution of effective th erapy. In addition to clinical utility, 
the MDA bone response criteria clos ely reflect the behavior of bone 
metastases on radiographs and CT and can be used as guidelines for the 
interpretation of these studies whethe r or not a patient is enrolled in a 
therapeutic trial. The MDA criteria can be considered for use in conjunction with other cancer response criteria or in patients with bone-
only metastases and no measurable disease.  Though the MDACC bone response cr iteria have been helpful in 
determining response to therapy in  bone metastasis, no imaging study 
exists to measure the be nefits of bisphosphonates in preventing skeletal 
related events in patients with metastatic breast cancer. Such limitations, combined with the expense of tradit ional imaging studies, suggest a need 
for novel measures of tumor response and bone health.  Ntx, a marker of bone resorption, has been found to signi ficantly correlate with risk of 
negative clinical outcomes(28), res ponse to systemic therapy(29) and 
response to bisphosphonate therapy(25).   Ntx has shown significant correlation with clinically relevant skeletal 
related events (SREs) (r=0.62, p<0.001) in  patients with bone metastasis 
and in a multivariate logistic regression model was highly predictive for adverse event or death (30). In  randomized bisphosphonate studies, 
reductions in Ntx and decreased SREs we re similar in patients treated with 
zoledronic acid compared to pamidronate (23).  Several studies have correl ated reductions in Ntx w ith response to therapy. 
Costa et al. demonstrated that increas es in Ntx were strongly associated 
with progression in bone and that  the increase in Ntx occurred 
independent of bisphosphonate administ ration(31). In this study, urinary 
Ntx was associated with the highest positive predictive value for disease progression (71%) when compared to other markers of bone metabolism.  
A second study conducted by Lipton, et al randomized patien ts to receive 
either pamidronate or placebo and corre lated urinary Ntx with response to 
therapy(32). Of the 25 patients who received pamidronate, 21 had elevated Ntx prior to therapy administration and 12 of these patients normalized 
Ntx values. When compared to the patients who did not normalize Ntx, the 
proportion of patients with progressi on in bone was significantly higher 
(p=0.03) in those who did not normaliz e. Although not di rectly correlated 
with tumor response, several bisp hosphonate dosing studies have also 
demonstrated a dose dependant effect on Ntx levels [summarized in (33)], 
suggesting that variations in bone reso rption for individual  patients can be 
detected using this technique. Finally, the existing clinical data for the use of Ntx to monitor response to bisphosphonate therapy has led to development and implementation of the Bisphosphonate Therapy Directed 
by Bone Resorption Markers (BISMARK ) trial. This study is a large 
31 
 March 28, 2011
randomized phase III trial currently  accruing patients to prove non-
inferiority between standard and marke r-directed bisphosphonate therapy.    
  
Because this proposal hypothesizes that  combined therapy with dasatinib 
and zoledronic acid will inhibit bon e resorption through combined effects 
on osteoclasts and may also exert anti- tumor effects through disruption of 
the tumor cell/osteoclast paracrine loop, biomarkers of bone resorption 
would be expected to accurately pred ict improvement in bone health as 
well as tumor response and time to disease progression in this special 
cohort of patients.   Urinary measures of Ntx will be performed using standard techniques at baseline, 1 month, 3 mont hs and then every 3
rd month until disease 
progression or protocol withdrawal. Patients will be divided into three categories: high (Ntx>
 100nm/mmol creatinine) , moderate (Ntx=50-
99nm/mmol creatinine) and low (N tx <50nm/mmol creatinine) as 
previously described by Coleman et al .(25). This study demonstrated that 
treatment with various systemic therapies in combination with zoledronic acid resulted in a 67% de crease in the proportion of patients with moderate 
to high levels of Ntx after only one m onth of therapy; an effect which was 
sustained for > 6 months. Zoledronic acid was also more effective than 
pamidronate in reducing the levels of Ntx from a moderate or high state to a low state within the breast cancer subset, a subset in which zoledronic acid significantly improved clinical  benefit compared to pamidronate. 
 
4 OVERVIEW OF STUDY DESIGN AND EVALUATION 
4.1 Dose-finding and Cohort Definitions 
This is an open label, Phase I/II, dose escalation study to evaluate the 
safety and tolerability of dasatanib in combination with a standard 28-day cycle of zoledronic acid (Figure 4.1) in  patients with metastatic breast 
cancer to bone.  
 Zoledronic Acid IV1
Dasatinib1PO daily x 28 days
Cycle=28 daysFigure 4.1: Dosing Schedule for Phase I and Phase II
1. Dosing as per protocol section 7.3.
32 
 March 28, 2011
Zoledronic acid will be administered as a 15-minute infusion on day 1(+/- 
48 hours) of a 28-day cycle. The dose of  zoledronic acid administered will 
be calculated using the standard do sing guidelines outlined in section 
7.3.2. 
 Dasatinib will be taken by mouth usi ng a daily dosing schedule on days 1-
28 of each cycle (i.e. continuous dosing). Dasatinib will be given 
continuously unless patients develop t oxicity requiring dose adjustment as 
outlined in section 7.4. 
 
4.2  Phase I Study Design 
The primary objective of the phase I portion of this trial will be to 
determine the RP2D for dasatinib in combination with zoledronic acid.  
 The first 3 patients (dosing cohort 1)  will be treated with 100 mg of 
dasatinib daily in combination with full dose zoledronic acid using the 
dosing guidelines outlined  in section 7.3.2. If <
 1 of 3 patients develops 
DLT within cycle one of therapy, then 3 additional patients will be accrued to this dose level .  If <
 1 of  3 patients treated in dosing cohort 1 develops DLT within cycle 
one of therapy, then 3 additional patients will be accrued to this cohort (n=6 total). If <
 1 of 6 enrolled patients experiences DLT, then this will be 
deemed the RP2D and accrual will begin for the phase 2 portion of the trial.  
If >
 2 patients develop DLT during initial  accrual (n=3) or  during the dose 
expansion (n=6 total) of any cohort, further accrual will begin at the lower 
dosing cohort until a total of six pati ents are treated at the lower dosing 
cohort or accrual is halted due to DLT. The RP2D will be defined as the 
dose at which <  1 out of 6 patients develops DLT. 
If > 2 patients develop DLT during accrual to cohort – 1 (100 mg of 
dasatinib daily), the study will be closed due to intolerability. 
4.2.1 Definition of Dose Limiting Toxicity 
Toxicity will be assessed using th e NCI Common Toxicity Criteria (CTC) 
Scale, version 3.0.   By definition a DLT must occur during cycle 1, be suspected as being drug-related, and includes any of the following: 
 Any grade 4 non-hematological toxicity 
 Grade 4 neutropenia lasting > 7 da ys or any febrile neutropenia 
33 
 March 28, 2011
 Grade 3 non-hematological toxicity  that persists >72 hours despite 
adequate supportive care  
 Grade 2 or greater ne utropenia (ANC<1.5x109/L) or thrombocytopenia 
(PLT<75x109/L) which fails to revert to grade 1 (level at which 
treatment is permitted) by the time of the scheduled start of cycle 2  
 50% decrease in calculat ed creatinine clearance 
 Diagnosis of osteonecrosis of the jaw 
 
4.3 Phase II Study Design 
The dose identified as the RP2D in the phase I portion of this study will be 
evaluated for efficacy in the phase II portion of this trial. The primary 
objective of this phase II study is to assess the efficacy of dasatinib in 
combination with zoledronic acid as  measured by disease response. .  
Patients will be stratified into tw o cohorts dependent upon Ntx levels 
obtained prior to the ini tiation of therapy (Figur e 4.2). All patients will 
receive same therapy, lab draws and radiographic assessment for response.  
 
Figure 4.2: Phase II Trial Design
Initial Registration 
Baseline measurement of NtxPatients with High 
(>100nM/mmol) 
or Moderate (50-
99nM/mmol) 
levels of Ntx
Patients with Low 
(< 50nM/mmol) 
levels of Ntx
StratifyZoledronic Acid IV Q 4 
weeks + Dasatinib PO (Dose established by Phase I portion of trial)
Repeat measurement of Ntx
1 monthRepeat measurement of Ntxand radiographic 
assessment of response (repeat Q 3months)
2 monthFigure 4.2: Phase II Trial Design
Initial Registration 
Baseline measurement of NtxPatients with High 
(>100nM/mmol) 
or Moderate (50-
99nM/mmol) 
levels of Ntx
Patients with Low 
(< 50nM/mmol) 
levels of Ntx
StratifyZoledronic Acid IV Q 4 weeks + Dasatinib PO (Dose established by Phase I portion of trial)
Repeat measurement of Ntx
1 monthRepeat measurement of Ntxand radiographic 
assessment of response (repeat Q 3months)
2 month
 
The prim
ary efficacy analysis will not be dependant upon urinary Ntx 
levels, but this the effects of therap y on urinary Ntx will be evaluated as a 
secondary endpoint. 
Patients treated at the RP2D (n=6) in the phase I portion of this study will 
be included in the efficacy analysis  for the phase II portion of the trial. 
34 
 March 28, 2011
Up to 25 patients will be enrolled in the phase II study to assess the 
efficacy of dasatinib in combination with zometa (zoledronic acid).  The 
primary endpoint is the response rate.  The trial will be conducted by the 
Simon’s two-stage design using the minimax criterion and the response rate will be estimated accordingly.  It is assumed that dasatinib in combination with zometa will have a target response rate of 25%.  A response rate of  5% or lower is considered a 
failure.  When the probability of acc epting a “bad” regimen (i.e. response 
rate  5%) is 0.05 and the proba bility of rejecting a “good” regimen (i.e. 
response rate  25%) is  0.10, Simon’s design to minimize the maximum 
sample size requires 15 patients in the fi rst stage.  If no patients respond to 
the treatment, the trial will be stopped and the regimen will be declared as 
ineffective.  If at least one of the first 15 patients respond to the treatment, 
10 additional patients will be entered in the study to reach a total of 25 
patients.  By the end of the study, th e new regimen will be rejected if 
response rate is less than or equal to 3 out of 25 patients and will be 
accepted otherwise.  The operating charac teristics of the trial are given as 
follows.  When the true response ra te is 0.05, the probability of stopping 
the trial early is 46.3%.  On the othe r hand, if the true response rate is 
0.25, the probability to stop the trial ea rly is 1.3%.  The expected sample 
sizes are 20.37 and 24.97 when the true response rates are 0.05 and 0.25, respectively.  At the end of the st udy, the response rate and the 95% 
confidence interval will be reported and the toxicity profile of the regimen will be summarized.  If the trial conti nues to the second stage (i.e., accrual 
= 25) and the 5 of 25 patients response  for a point estimate of 20.0%, the 
exact binomial 95% confidence inte rval would be (6.8%, 40.7%). 
Assuming that 10% of patients may not be evaluable for response, a total 
of 28 patients will be acc rued to the study.    
5 STUDY OBJECTIVES 
5.1 Primary Objective  
5.1.1 Phase 
5.1.2 Phase I: 
To determine the maximum tolerated dose (MTD) and recommended 
phase II dose (RP2D) for dasatinib in combination with zoledronic acid. 
II: 
Determine the efficacy of dasatinib in combination with zoledronic acid as 
measured by disease response. 
35 
 March 28, 2011
5.2 Secondary Objective(s) 
5.2.1 Phase 
5.2.2 Phase I: 
To determine toxicity of combin ation therapy with dasatinib and 
zoledronic acid in patients with  breast cancer and bone metastasis.  
II: 
 Determine the effects of therapy on urinary Ntx levels. 
 Changes in Ntx levels will be correl ated with traditional measurements 
of tumor response in bone (using  WHO criteria), progression free 
survival and overall survival at 2years 
 Biologic characterizatio n of response using 18F-FDG PET 
 Determination of molecular corre lates of response in paraffin 
embedded or frozen tissue 
 Determine time to tumor progressio n, response (as defined in section 
9.1.2), time to tumor response, progression free survival (PFS) up to 2 
years 
 Determine overall survival (OS) at 2 years 
 Banking of blood for future studies of novel markers of bone health 
 Correlate response with tumor estrogen receptor (ER), progesterone receptor (PR) and HER2 status  
 
 
6 SELECTION OF PATIENTS 
6.1 Inclusion Criteria  
For entry into the study, the following criteria MUST be met: 
1) Patients must have a pathologically confirmed diagnosis of 
invasive carcinoma of the breast.  
2) Patients must carry a diagnosis of metastatic breast cancer with 
predominant bone involvement. For the purposes of this study, 
predominant bone involvement will be defined as radiographically 
detected bone metastasis in the presence or absence of other sites of metastatic breast cancer (i.e. vis ceral involvement).  If visceral 
involvement is present, patients mu st be asymptomatic and have no 
tumors in visceral organs that measure >3cm in size.  
3) Patients must agree to serial urine collections for measurement of 
Ntx according to the schedule defined in sections 8 and 9.  
4) Age >
18 years.  
5) Patients must be able to swallow oral medications. Dasatinib must 
be taken whole and cannot be crushed.  
36 
 March 28, 2011
6) Patients must have evaluable disease using WHO Criteria for 
Assessment of Disease Response in B one or MDACC Modified Response 
Criteria for Assessment of Disease Response in Bone (Post text 
supplement 4).  
7) Patients must not have had >1 chemotherapy regimens for 
metastatic disease. Patients with metastasis diagnosed < 6 months after 
completion of adjuvant chemotherapy are considered to have had chemotherapy for metastatic breast cancer.  
8) Patients with ER positive disease must have had disease 
progression on at least one prior hormona l therapy for metastatic disease. 
Patients must also have developed dis ease progression on their most recent 
hormonal therapy regimen and be agreeable to continue this regimen in combination with protocol therapy. Fo r the purposes of this study disease 
progression while receiving hormonal therapy will be defined as:  
 Radiographic evidence of progressi ve disease according to RECIST 
or WHO criteria for measurement of response in bone  
 Progression of disease by physical exam in patients with skin 
involvement  
 25% increase in tumor marker as measured on two evaluations no 
less than 72 hours apart  
9) Patients must have and ECOG performance status of < 2.  
10) Patients must not require concur rent radiation or chemotherapy 
while receiving protocol therapy.  
11) Patients must not have an active infection requiring the use of 
intravenous antibiotics. The use of oral antibiotics as prophylaxis is 
allowed.  
12) Patients must have a baseline ECG with QTc within the normal 
range within 28 days prior to registration.  
13) Patients must be informed of the investigational nature of the study 
and must sign and give written informed consent.  
14) Patients may have received prev ious radiation but must have 
completed radiation at least 2 weeks (8  weeks for radiation to the brain) 
prior to registration. Patients with i rradiated tumor as the only site of 
evaluable disease will not be eligible for protocol therapy unless there is 
documented disease progression within the previously radiated site.  
15) Patients must have recovered to grade < 1 from all acute toxicity of 
previous radiation or hormonal therapy.  
 Adequate hematologic and hepatic function: 
 Granulocyte count >  1,500/mcL  
 Platelet count >  100,000/mcL  
 Bilirubin <  1.5 x ULN  
 AST and/or ALT <  2 x ULN  
 Alkaline phosphatase (liver component, if fractionated) <  2 x ULN  
 Serum Na, K+, Mg2+, Phosphate and Ca2+ Lower Limit of 
Normal (LLN) [subjects with low elect rolyte levels must be repleted 
to normal for protocol entry]  
37 
 March 28, 2011
16) Patients must not receive any c oncurrent bisphosphonate therapy 
other than that pres cribed by the study. 
17) Sexually active patients with repr oductive potential must agree to 
use an effective method of birth cont rol during the course of the study and 
for no less than 4 weeks after di scontinuing study drug. Contraceptives 
must be used in a manner such that risk of failure is minimized. Oral 
contraceptives should be avoided in wo men with estrogen or progesterone 
receptor positive breast cancer.  
18) Prior to study enrollment, women of childbearing potential 
(WOCBP) must be advised of the importance of avoiding pregnancy 
during trial participation and the poten tial risk factors fo r an unintentional 
pregnancy.  In addition, men enrolled on this study should understand the 
risks to any sexual partner of childbe aring potential and should practice an 
effective method of birth control. 
19) All WOCBP MUST have a negative serum or urine pregnancy test 
within 72 hours prior to the start of study drug administration. If the 
pregnancy test is positive, the patient must not receive investigational 
product and must not be enrolled in the study. 
20) Patients with disease progression while receiving previous therapy 
in combination with bisphosphonates (i ncluding zoledron ic acid) will be 
considered eligible for protocol participation.  
 
6.2 Exclusion Criteria 
Subjects may NOT have any of the following:  
 
1) Any malignancy (other than breast cancer) that require d radiotherapy 
or systemic treatment within the past 5 years.  
2) Concurrent medical condition which ma y increase the risk of toxicity, 
including: 
 Pleural or pericardial effusion of any grade 
 Clinically-significant coagulation or  platelet function disorder (e.g. 
known von Willebrand’s disease) 
3) Cardiac Symptoms, including the following:  
 Uncontrolled angina, congestive heart failure or MI w ithin (6 months) 
 Diagnosed congenital long QT syndrome 
 Any history of clinically significan t ventricular arrhythmias (such as 
ventricular tachycardia, ventricular fibrillation, or Torsades de pointes) 
 Prolonged QTc interval on pre-entr y electrocardiogram (> normal 
range) 
 Subjects with hypokalemia or hypomagnesemia if it cannot be 
corrected 
38 
 March 28, 2011
4) History of significant bleeding disord er unrelated to cancer, including: 
 Diagnosed congenital bleeding disorders (e.g., von Willebrand’s 
disease) 
 Diagnosed acquired bleeding disorder  within one year (e.g., acquired 
anti-factor VIII antibodies) 
 Ongoing or recent (  3 months) significant ga strointestinal bleeding 
5) Concomitant Medications, consider the following prohibitions (Drugs 
must be discontinued for 7 days prio r to starting protocol therapy):  
 Drugs that are generally accepted to have a risk of causing Torsades de 
Pointes including:  
quinidine, procainamide, disopyramide, amiodarone, sotalol, ibutilide, 
dofetilide 
erythromycins, clarithromycin, chlorpromazine, haloperidol, 
mesoridazine, thioridazine, pimozide , cisapride, bepridil, droperidol, 
methadone, arsenic, chloroquine, domperidone, halofantrine, levomethadyl, pentamidine, sparfloxacin, lidoflazine. 
 The concomitant use of H2 blockers  or proton pump inhibitors with 
dasatinib is not recommended. The use of antacids should be considered 
in place of H2 blockers or proton pump  inhibitors in patients receiving 
dasatinib therapy. 
 Patient agrees to discontinue St. Jo hns Wort while receiving dasatinib 
therapy   Patient may not be receiving any pr ohibited CYP3A4 inhibitors [see 
section 7.6] 
6) Women and men of child bearing potential: 
 Who are unwilling or unable to use an acceptable method to avoid 
pregnancy for the entire study period and for at least 4 weeks after 
cessation of study drug, or  Women of childbearing potential  (CBP) who have a positive 
pregnancy test at baseline, or  Women who are pregnant or breastfeeding  
 Sexually active men and women capable of reproduction must use an 
effective method of birth control dur ing the course of the study, in a 
manner such that risk of failure is minimized  Prior to study enrollment, men an d women capable of reproduction 
must be advised of the importance of avoiding pre gnancy during trial 
participation and the potential risk fact ors for an unintentional pregnancy   
7) Prisoners or subjects who are compulsorily detained (involuntarily 
incarcerated) for treatment of either  a psychiatric or physical (e.g., 
infectious) illness  
8) Untreated or uncontrolled brain metastasis  
9) Patien
t inability to take or absorb oral medications  
39 
 March 28, 2011
10) Current active dental problems in cluding: ongoing infection of the 
teeth or jawbone (maxilla or mandi bula); current expos ed bone in the 
mouth; and current or prior diagnos is of osteonecrosis of the jaw 
11) Recent (within 8 weeks) or planned dental or jaw surgery (e.g., 
extraction, implants)  
12) Diagnosis of metabolic bone diseas e other than osteoporosis (e.g., 
Paget’s disease of bone)  
13) Known hypersensitivity to zoledronic acid or aspirin  
14) Corrected serum calcium  8.0 mg/dL (2.0 mmol/L) or  12.0 mg/dL 
(3.0 mmol/L) at Visit 1.  The formula to be used is:  Corrected serum 
calcium (mg/dL) = Patient’s serum calcium (mg/dL) + [0.8 x Midrange 
Albumin (g/dL) – Patient’s Albumin (g /dL)].  4.0g/dL to be used for the 
Midrange Albumin  
15) Serum creatinine  1.5 times the institutional upper limits of normal or 
a creatinine clearance of <40 ml/min  when calculated by the Cockroft and 
Gault formula: 
Estimated creatinine clearance=  (140-age in years) x (weight in kg)
  (x 0.85, if female) 
                             72 x creatinine (mg/dL) 
 
7 TREATMENT OF SUBJECTS 
This is an open label, Phase I/II, dose escalation study to evaluate the 
safety and tolerability of dasatanib in combination with a standard 28-day 
cycle of zoledronic acid in patients with metastatic breast cancer to bone. Zoledronic acid will be administered as a 15-minute infusion on day 1(+/- 
48 hours) of a 28-day cycle (see sect ion 7.3.2). Dasatinib will be taken by 
mouth using a daily dosing schedule on days 1-28 of each cycle (i.e. 
continuous administration). Dasatinib will be given continuously unless 
patients develop toxicity requiring dose  adjustment as outlined in section 
7.4.  Patients with ER positive disease w ho have progressed on their most 
recent hormonal therapy will continue this therapy (at the previously prescribed dose) in combination with protocol treatment. 
 
7.1 Study Registration 
Patients will be registered after the Principal Investigator or her designee 
has verified that they are eligible per criteria in Section 6.1 and Section 6.2. Patients withdrawn from the study pr ior to completing the first course 
of therapy due to non drug-rela ted reasons will be replaced.  
 
40 
 March 28, 2011
The Principal Investigator or he r designee will provide the dosing 
assignment form. No subject may start therapy prior to dosing assignment.  
 
7.2 Study Treatment 
7.2.1 Phase I 
On cycle 1, day 1, patients will rece ive a single IV infusion of zoledronic 
acid using dosing guidelines outlined in section 6.4.2. Dasatinib will be 
taken daily by mouth beginning on cycl e 1 day 1 and continued daily for 
the duration of the cycle (Tab le 7.1 and section 4.2).   
 
Table 7.1.  Dosing of Dasatinib for Phase I Dosing 
Cohorts  
Dose Level Dose of Dasatinib (+ Full Dose Zoledronic Acid) 
-1 70 mg po daily 
1 100 mg po daily 
 
Patients will be monitored for toxicity every week during th e first cycle of 
therapy and on day 1 (+/- 48 hours) prio r to therapy for subsequent cycles. 
ECG and laboratory assessments will be performed weekly (see section 
7.0) during the first cycle. ECG will be performed on day 1 (+/- 48 hours) 
of cycle 2 only.  Laboratory assessment will be performed on day 1 (+/- 48 hours) prior to therapy during cycle 2 and all subsequent cycles.   
 
7.2.2 Phase II 
Zoledronic acid will be administered  as a single 15-minute infusion on day 
1(+/- 48 hours) of a 28-day cycle.  The dose of zoledronic acid 
administered will be calculated using the standard dosing guidelines outlined in section 7.3.2.  Dasatinib will be taken by mouth usi ng a daily dosing schedule on days 1-
28 of each cycle (i.e. continuous dosing). Dasatinib will be given 
continuously unless patients develop t oxicity requiring dose adjustment as 
outlined in section 7.4.  Both drugs will be given at the RP2D as determined by the phase I portion of the trial.   Patients will be monitored for toxic ity on day 1 (+/- 48 hours) prior to 
therapy during subsequent cycles . Physical exams and laboratory 
41 
 March 28, 2011
assessments will be performed mont hly (see section 8.0)  on day 1 (+/- 48 
hours) prior to therapy.  Measurement of  Ntx will occur at baseline (up to 
7 days prior to therapy), at day 28 (+ /- 48 hours) of cycle 1 and at day 28 
(+/- 48 hours) of every 3rd cycle of therapy, (see figure 4.2 and section 
8.0). Patients will undergo radiogra phic evaluation of response every 3 
cycles.  
7.3 Drug Dosing and Routes of Administration 
NOTE: Although the dose of dasatinib may differ between the phase I 
and phase II portions of the tr ial, the schedule and route of 
administration of both dasatinib and zoledronic acid will be the same for the phase I and phase II portions of the trial. 
7.3.1 Dasatinib 
7.3Dasatinib will be supplied as 20 and 50 mg tablets for oral administration. 
Patients treated at the 70 mg dose leve l will receive a 50 mg tablet and a 
20 mg tablet daily. Patients treated at the 100 mg dose level will receive 
two 50 mg tablets daily.   If a dose is missed by more than 12 hours, the dose should be omitted. Missed doses should not be made up.   Tablets should not be crushed or cut; they should be swallowed whole.  
Dasatinib can be taken with or without a meal.  Patients will be provided with a diar y to record drug dosing (see Appendix 
3).  
.2 Zoledronic Acid 
Zoledronic acid will be administer ed as a 15-minute IV infusion on day 
1(+/- 48 hours) of each 28-day cycle. The dose of zoledronic acid administered will be calculated using the schema in Figure 7.1. 
 
Figure 7.1: Dosing of zoledronic acid 
Dosing will be based upon serum creatin ine obtained within 2 weeks prior to 
zoledronate dose.  
 
Creatinine Clearance =(140 – age in years) x (weight in kg)     (x 0.85, if female)  
                                                           72 x serum Creatinine 
Creatinine Clearance (mL/ min) Zoledronic acid Dose 
>60 4 mg 
50-60 3.5 mg 
40-49 3.3 mg 
30-39 3 mg 
42 
 March 28, 2011
<30 Hold 
  
Doses of zoledronic acid may not be  given earlier than 48 hours prior to 
day 1 of each cycle of therapy; however doses of zoledronic acid may be 
delayed for up to 4 weeks if the delay in  therapy is felt to be in the best 
interest of the patient. The duration and reason for the delay should be 
documented on the appropriate treatment forms. Patients should continue with laboratory and toxicity assessments as outlined in section 8.0.  Patients requiring a delay in therapy administration for >
 4 weeks will 
discontinue protocol therapy. Dasatini b may be administered as a single 
agent while zoledronic acid is held.   
Patients should receive supplementa l oral calcium (1000-2000 mg daily) 
and vitamin D (400-800 IU daily) unless felt to be medically 
contraindicated by the treating physician. 
 
7.4 Dose Modifications  
7.4.1 Dasatinib 
NOTE: Toxicity will be assessed  using the NCI Common Toxicity 
Criteria (CTC) Scale, version 3.0.  Dasatinib should be held for 
treatment related toxicities >  grade 2.  
 
Treatment modifications will proceed as outlined in Table 7.2.   
 
Table 7.2: Dose Modifications for Dasatinib. 
Dose Level Dose (if RP2D=100 mg 
daily) Dose (if RP2D=70 mg 
daily)  
A 70 mg daily 50 mg daily  
B 50 mg daily Discontinue protocol 
therapy  
C Discontinue protocol 
therapy   
Toxicity Treatment Modification 
Grade 1 Proceed without dose modification. Consider appropriate supportive 
measures. 
Grade 2 If 1st episode, hold therapy until recovery to Grade < 1, then continue 
treatment at dose level A. 
If 2nd episode, hold therapy until recovery to Grade < 1, then continue 
treatment at dose level B. 
43 
 March 28, 2011
If 3rd episode, discontinue protocol therapy 
 
Grade 3 If 1st episode, hold therapy until recovery to Grade < 1, then continue 
treatment at dose level B. 
If 2nd episode, discontinue protocol therapy 
Grade 4 May discontinue treatment permanently  or, at the discretion of the treating 
physician, hold therapy until recovery to Grade < 1, then continue treatment at 
dose level B. If any grade > 1 toxicity  recurs, patient must discontinue 
protocol therapy.  
 
Decisions for dose reductions will be ma de according to grade of toxicity 
and will be independent of the type of  toxicity. For example, if a patient 
develops grade 2 hypokalemia that resolves and, upon re-treatment, 
develops grade 2 elevation of AST; the second event (i.e. elevated AST) 
will require a dose reduction because it is the second episode of grade 2 
toxicity.   Zoledronic acid may be continued if dasatinib is held or discontinued. 
The dosing time may be adjusted as required. If doses are missed for 
toxicity, they should not be replaced. If a dose is not taken due to an error, 
it may be taken up to 12 hours later. If vomiting occurs within 30 minutes 
of intake, that dose may be repeated. 
7.4.2  Dose Modifications for Zoledronic Acid 
Dosing of zoledronic acid will be performed as outlined in section 7.3.2. 
Zoledronic acid will be permanently held in patients who develop evidence of osteonecrosis, acute renal failure attributed to therapy with zoledronic acid, or hypersensitivity to zoledronic acid that recurs despite 
appropriate prophylaxis. Patients may c ontinue single agent dasatinib if 
zoledronic acid is discontinued. 
7.5 Discontinuation of Therapy  
Study therapy must be immediately discontinued for the following 
reasons: 
 Progressive disease at any time 
 Any clinical adverse event, laboratory abnormality or intercurrent 
illness which, in the opinion of the Investigator, indicates that continued treatment with study therapy is  not in the best interest of the 
subject 
 Excessive toxicity de spite dose reduction 
 Withdrawal of informed consent (subject’s decision to withdraw for 
any reason) 
44 
 March 28, 2011
 Pregnancy  
 All WOCBP should be instructed to contact the Investigator 
immediately if they suspect they might be pregnant (e.g., missed 
or late menstrual period) at a ny time during study participation. 
Institutional policy and local regulations should determine the frequency of on study pregnancy te sts for WOCBP enrolled in the 
study. 
 The Investigator must immediatel y notify BMS in the event of a 
confirmed pregnancy in a pati ent participating in the study . 
7.5.1 
7.6 Follow up After Disc ontinuation of Protocol 
Therapy: 
All patients will be followed for 2 years after discontinuation of protocol 
therapy or until death, whichever occu rs first. Patients will follow up 1 
month after completing therapy for toxici ty assessment. After this, patients 
will be followed every 3-6 months for survival outcome. This follow up can include contacting an outside treating physician if the patient does not 
wish to return to the treating institution.  
7.6 Prohibited and Restricted Therapies During 
Study 
.1 Prohibited Therapies 
Subjects requiring any of the followi ng prohibited therap ies should not be 
enrolled.  
CYP3A4  
Dasatinib is primarily metabolized by the CYP3A4 enzyme. Therefore, 
potent inhibitors of CYP3A4 are prohibited during study; for such 
medications, a wash-out period of 7 days is required prior to starting 
Dasatinib. Subjects should be advised not to consume substantial quantities of grapefruit juice.  
Drugs that may increase dasatinib plasma concentrations 
CYP3A4 Inhibitors:  Dasatinib is a CYP3A4 substrate. Concomitant use 
of Dasatinib and drugs that inhibit CYP3A4 (See Appendix 2) may 
increase exposure to dasatinib and s hould be avoided. In patients receiving 
treatment with dasatinib, close monitoring for toxicity and a Dasatinib dose reduction should be considered if  systemic administration of a potent 
CYP3A4 inhibitor cannot be avoided.  
Medications that prolong QT Interval
 
Subjects enrolled in this study should not take or begin to take 
concomitant medications known to pr olong the QT inte rval. For such 
medications, a wash-out period of 7days is required prior to starting 
45 
 March 28, 2011
dasatinib. (Agents which may possibl y prolong the QT interval are 
restricted). Medications known to prol ong the QT interval (Class I; see 
http://www.qtdrugs.org/medical-pros/drug- lists/drug-lists.htm) are: Drugs 
that are generally accepted to have a risk of causing Torsades de Pointes 
include: 
 quinidine, procainamide, disopyramide 
 amiodarone, sotalol, ibutilide, dofetilide 
 erythromycins, clarithromycin 
 chlorpromazine, haloperidol, mesoridazine, thioridazine, pimozide 
 cisapride, bepridil, droperidol, methadone, arsenic, chloroquine, 
domperidone, halofantrine, levomethadyl, pentamidine, 
sparfloxacin, lidoflazine 
 Should the Investigator believe that  beginning therapy with a potentially 
QT prolonging medication (other than the ones explicitly  prohibited) is 
vital to an individual subj ect’s care, the Investigator must check that the 
subject’s prior on-therapy ECG has not shown a QTcF  450 msec or an 
increase in QTc  60 msec over the baseline value.  
7.6.2 Restricted Therapies 
Drugs that may decrease dasatinib plasma concentrations 
CYP3A4 Inducers:  Drugs that induce CYP3A4 activity may decrease 
dasatinib plasma concentrations. In  patients in whom CYP3A4 inducers 
(See Appendix 2) are indicated, alternative agents with less enzyme 
induction potential should be used.  If dasatinib must be administered with a CYP3A4 inducer, a dose increase in  dasatinib should be considered. 
Drugs that may have their plasma concentration altered by dasatinib 
CYP3A4 Substrates:  CYP3A4 substrates k nown to have a narrow 
therapeutic index such as alfentanil, astemizole, terfenadine, cisapride, 
cyclosporine, fentanyl, pimozide, quinidi ne, sirolimus, tacrolimus, or ergot 
alkaloids (ergotamine, dihydroergotamin e) should be administered with 
caution in patients receiving dasatinib.     
Less-potent inhibitors, indu cers, and substrates of CYP3A4 are restricted.  
(Appendix 2) 
St. John's wort ( Hypericum perforatum ) may decrease dasatinib plasma 
concentrations unpredictably.  Patients  receiving dasatini b should not take 
St. John's wort.  Antacids: Nonclinical data demonstrate that the solubility of dasatinib is 
pH dependent. Simultaneous administra tion of dasatinib with antacids 
should be avoided.  If an tacid therapy is needed, the antacid dose should 
be administered at least 2 hours pr ior to or 2 hours after the dose of 
dasatinib.  
46 
 March 28, 2011
H2 Blockers/Proton Pump Inhibitors:  Long-term suppression of gastric 
acid secretion by H 2 blockers or proton pump inhibitors (eg, famotidine 
and omeprazole) is likely to reduce dasatinib exposure. The concomitant 
use of H 2 blockers or proton pump inhib itors with dasatinib is not 
recommended. The use of antacids s hould be considered in place of H 2 
blockers or proton pump i nhibitors in patients recei ving dasatinib therapy.  
Medications that inhibit Platel et Function and Anticoagulants  
Caution should be exercised if patien ts are required to take medications 
that inhibit platelet f unction or anticoagulants. 
Subjects enrolled in this  study should not take concomitant medications 
which durably inhibit plat elet function. For such medications, a wash-out 
period of  7days is required prior to st arting dasatinib. (Agents which 
inhibit platelet function transien tly or inhibit coagulation by other 
mechanisms are restricted.)  
Medications which directly  and durably inhibit pl atelet function include: 
 aspirin or aspirin-containing comb inations, clopidogrel, dipyridamole 
 tirofiban, dipyridamole, epoproste nol, eptifibatide, cilostazol, 
abciximab, ticlopidine, cilostazol Medications which directly and durably inhibit anticoagulation 
include: 
 warfarin, heparin/low molecular weight heparin [e.g., danaparoid, 
dalteparin, tinzaparin, enoxaparin] 
 Exceptions: low-dose warfarin for prophylaxis to prevent catheter 
thrombosis, and heparin for flushes of IV lines.  
 
7.7 Concomitant Therapy 
NOTE: For the phase I portion of the trial, concomitant medications 
may be used to treat  symptoms that develop during therapy; however, 
the routine use of concomitant medi cations (except antibiotics) as 
prophylaxis  for toxicity is not allowed during cycle 1 of therapy. 
Concomitant medications can be us ed as prophylaxis for toxicity 
during cycles > 1.   
In general, the use of any concurre nt medications deemed necessary for 
the care of the patient are allowed. Fo r patients receiving cycles > 1 in the 
phase I portion of the trial and for a ll patients enrolled in the phase II 
portion of the trial, drugs may be given prophylactically to reduce the side 
effects of therapy. The following exceptions apply: 
 No other investigational therapy will be given to patients. 
47 
 March 28, 2011
48  The use of anticancer agents (oth er than hormonal therapy) or 
radiation therapy is not allowed (an exception would be the use of 
megestrol acetate for the treatment of anorexia). 
 Patients enrolled in the Phase I portion of the trial may not receive 
GCSF or GMCSF during cycle 1 of therapy.  The use of 
hematologic growth factors for the treatment of anemia is allowed at any time during protocol thera py. Patients enrolled in the Phase 
II portion of the trial or those w ho have completed >1 cycle of 
therapy in the phase I portion of th e trial may receive growth factor 
support as per ASCO guidelines.  
 Where possible, drugs known to inhibit CYP3A4 should be avoided as systemic therapy as a pharmacokinetic interaction may occur during the concomitant use of dasatinib (see section 7.5).  
 
 
 
 March 28, 2011 ja a 
49 8 STUDY PROCEDURES  
8.1 Evaluation and visit schedule 
Table 8.1 Evaluation and visit schedule in Phase I  
Dasatinib + Zoledronic Acid Final 
visit Screening 
Cycle 1 Continuing Cycles   
 
 
 
Evaluations: D-14 to D- 0 Day 1 Day 8 Day 15  Day 21 Day 28 Day 1  Day 8 Day 15 Day 21 Every 3rd 
Cycle  
Selection (inclusion/exclus ion criteria), medical 
history, demography, signed informed consent  X            
Physical exam3, ECOG performance status X X  X   X    X X 
Blood pressure, pulse, temperature,  weight X X  X   X     X 
Laboratory1: hematology, seru m biochemistry, 
urinal ysis X X1 X X X  X     X 
Pregnancy Test X8            
Calculate Creatinine Clearance X X X X X  X     X 
Concomitant medications X Continuous  ----------------------------------------------------------------------------------------- --------------------------------  
Adverse events, toxicity  Continuous  ----------------------------------------------------------------------------------------- --------------------------------  
ECG5 X X X X X  X5      
Tumor evaluation/staging2 (Radiographic 
imaging and/or turmor markers) X          X  
Treatment: Dasatinib3  Continuous  ---------------------------------------------------------------------------------------------------------------  
   Zoledronic Acid3  X     X      
Response Assessment:   Ntx4 X     X     X  
                                         Imaging Studies2 X          X  
Correlative Studies (optional):              
                         PET scan X   X        X6 
                         Biopsy X     X       
                         Blood Samples7 X     X7     X X6 
 a 
50 March 28, 2011 ja 
1. May be drawn on day 1 (+/- 48 hours) however, results must be reviewed prior to patient receiving day 1 of therapy.  Hematol ogy: hemoglobin, hematocrit, platelets, 
total white blood cell count (WBC) and differential. Serum biochem istry: sodium, potassium, chlo ride, bicarbonate, creatinine, blood urea nitrogen, albumin, total protein, 
SGOT (AST), SGPT (ALT), total bilirubin, alkaline phosphatase, ur ic acid, calcium, Glucose, magnesium. Urinalysis will only be performed during cycle 1 of therapy. 
Screening lab may be used for day 1 cycle 1 of therapy. 
2. Baseline scans may be performed 1 month prior to initiating prot ocol therapy. All known sites of metastasis must be imaged p rior to initiating protocol therapy. For 
response assessment, only imaging studies with detectable tumo r-related abnormalities will be required to follow response. Bone  scan will be performed pretreatment 
and used as a baseline for comparison, if needed, to verify dis ease progression or response as assessed using plain films.  
3. Physical exam must be performed on day 1 (+/- 48 hours) of cycles 1 and 2 and occur prior to administration of protocol ther apy. After cycle 2, physical exams can be 
performed every 2 cycles of therapy. 
4. Urine for N-telopeptide. Must be collected as sch eduled on day 28 (+/- 48 hours) of cycle 1 and every 3rd cycle of therapy(after 8 weks of treatment are completed and 
restagning takes place). Must be collected  before receiving subsequent cycles of therapy.  
5. ECG will only be performed during cycles 1 and 2 of therapy. Sc reening ECG may be performed up to 28 days prior to protocol therapy. 
6. PET scan will be done at time of disease progression to restage patients. Blood samples will be drawn at the time of documen ted disease progression (+/- 14 days). 
7. Blood will be collected for MUC-1 (CA27-29) levels and serum will be banked. Blood will be drawn during weeks 4, 8, 16 and 2 4. May be drawn +/- 72 hours of time 
points indicated but must be drawn prior  to administration of therapy. 
8. Must be performed in women of childbearing potenti al within 72 hours of dasatinib administration. 
 
 March 28, 2011 ja a 
51 Table 8.2 Evaluation and visit schedule in Phase II 
Dasatinib + Zoledronic Acid Final 
visit Screening 
Cycle 1 Continuing Cycles   
 
 
Evaluations: D-14 to D- 0 Day 1 Day 8 Day 15  Day 21 Day 28 Day 1  Day 8 Day 15 Day 21 Every 3rd 
Cycle  
Selection (inclusion/exclus ion criteria), medical 
history, demography, signed informed consent  X            
Physical exam3, ECOG performance status X X     X     X 
Blood pressure, pulse, temperature,  weight X X     X     X 
Laboratory1: hematology, serum biochemistry, X X1     X     X 
Pregnancy test X8            
Calculate Creatinine Clearance X X     X     X 
Concomitant medications X Continuous  ----------------------------------------------------------------------------------------- -----------------------------------------  
Adverse events, toxicity  Continuous  ----------------------------------------------------------------------------------------- -----------------------------------------  
ECG6 X     X       
Tumor evaluation/staging2 (Radiographic 
imaging and/or tumor markers) X      X    X  
Treatment: Dasatinib3  Continuous  ------------------------------------------------------------------------------------------------------------  
   Zoledronic Acid3  X     X      
Response Assessment:   Ntx4 X4     X     X  
                                         Imaging Studies2 X          X  
Correlative Studies (optional):             
                         PET scan X   X        X6 
                         Biopsy X     X       
                         Blood Samples7 X      X7     X6 
1. May be drawn on day 1 (+/- 48 hours) however, results must be reviewed prior to patient receiving day 1 of therapy.  Hematol ogy: hemoglobin, hematocrit, platelets, total 
white blood cell count (WBC) and differential. Serum biochemistr y: sodium, potassium, chloride, bicarbonate, creatinine, blood urea nitrogen, albumin, total protein, SGOT 
(AST), SGPT (ALT), total bilirubin, alkaline phosphatase, uric acid, calcium, Glucose, magnesiu m. Screening lab may be used for  day 1 cycle 1 of therapy. 
 a a 
52 March 28, 2011 j
2. Baseline scans may be performed 1 month prior to initiating treatment. All known sites of metastasis must be imaged prior to  initiating protocol therapy. For response 
assessment, only imaging studies with detectable tumor-related abnormalities will be required to follow response. Bone scan wil l be performed pretreatment and used as a 
baseline for comparison if needed to verify disease progression or response as a ssessed using plain films. 
3. Physical exam must be performed on day 1 (+/- 48 hours) of  cycles one and two and occur prior to administration of protocol therapy.  After cycle 2 of therapy, physical 
exam may be performed every 2 cycles. 
4. Urine for N-telopeptide. Must be collected as scheduled  on day 28 (+/- 48 hours) of cycle 1 and every 3rd cycle of therapy(after 8 weeks of treatment are completed and 
restaging takes place). Must be collected  before receiving subsequent cycles of t herapy. Accrual to the low Ntx cohort will be capped after 10 patients. If > 10 patient s with 
low levels of Ntx are accrued prior to study completion,  patients will undergo screening Ntx prior to study entry.   
5. Screening ECG may be performed up to 28 days prior to protocol therapy. 
6. PET scan will be done at time of disease progression to restage patients. Blood samples will be drawn at the time of documen ted disease progression (+/- 14 days). 
7.  Blood will be collected for MUC-1 (CA27-29) levels and resear ch serum will be banked. Research blood will be drawn during w eeks 4, 8, 16 and 24. May be drawn +/- 48 
hours of time points indicated but must be drawn prior  to administration of therapy. (Cycle =28 days/4 weeks) 
8. Must be performed in women of childbearing potenti al within 72 hours of dasatinib administration. 
 
 
 March 28, 2011
9 EFFICACY AND SAFETY ASSESSMENTS 
9.1 Efficacy Assessment 
9.1.1 
9.1.2 Measurement of Tumor Response 
Tumor response will be assessed for individual patients and will be used to determine 
which patients should continue protocol therap y in the absence of toxicity.  Patients 
with bone only involvement or disease c onsidered non-measurable by RECIST will be 
followed for response using the WHO Criteria for Assessment of Disease Response in Bone or the MDACC Modified Response Criter ia for Assessment of Disease Response 
in Bone  (Post-text supplement 4). Patients with measurable disease outside of the bone 
will have response measured using a combination of RECIST criteria (Post-text 
supplement 3) and the WHO Criteria for A ssessment of Disease Response in Bone 
(Post-text supplement 4).   Patients who meet criteria for disease pr ogression within the bone (as measured by 
WHO criteria) or in non-bone disease (as measured by RECIST criteria) or both will be considered to have progression of disease and will be withdrawn from protocol therapy.  
 It is feasible that patients  may have response in bone meta stasis and disease progression 
in non-bone metastasis. Because these patients have met criteria for disease progression, 
they will discontinue protocol therapy; however, (for statistical purposes only) patients with disease progression by RECIST in areas outside of the bone but disease response   
in the bone will be counted as responders for the purpose of correlation of bone 
response with changes in Ntx. Such patients will be counted as non-responders for all 
other endpoint analyses.   Radiologic assessments must account for all le sions that were present at screening and 
must use the same imaging techniques that  were used at screening. Any bone lesions 
that have been previously treated with radi ation therapy or surgic al resection should not 
be used for tumor assessment unless the lesions have shown definite progression since treatment.   
N-telopeptide of Type I Collagen (Ntx) 
Ntx, a marker of bone resorption, has been found to significantly correlate with risk of negative clinical outcomes(28), response to  systemic therapy(29) and response to 
bisphosphonate therapy(25). Because this pr oposal hypothesizes that combined therapy 
with dasatinib and zoledronic acid will exert anti-tumor effects through disruption of the 
tumor cell/osteoclast paracrine loop, biomarke rs of bone resorption would be expected 
to accurately predict tumor response and time to disease progression in this special 
cohort of patients. Urinary measures of Ntx will be performed using standard techniques at baseline, 1 mont h, 3 months and then every 3
rd months until disease 
progression or protoc ol withdrawal.  
 
53 
 March 28, 2011
Urine for Ntx analysis will be obtained on day 28 (+/- 48 hours) of cycle 1, cycle 3 and 
every subsequent 3rd cycle while the patient is receiving protocol therapy.  Urine will be 
obtained during the second morning void prior to  day 1 of specified cycles.  Assessment 
of Ntx will be performed through an outside lab using a commercially available assay. 
 
Although Ntx will be used as an endpoint for efficacy analysis and statistical design, changes in Ntx will not be us ed for decisions regarding co ntinuation of therapy on an 
individual patient basis.  
 
9.2 Safety Assessment 
Safety assessments will consist of monitori ng and recording all adverse events (AEs) 
and serious adverse events (SAEs), the regular monitoring of hematology, blood 
chemistry and urine values, regular measur ement of vital signs, and performance of 
physical examinations. The AE and SAE reporti ng period will begi n with the signing of 
informed consent and end 30 days after di scontinuation of protoc ol therapy. Reporting 
of AEs and SAEs will be as designated in section 11.   
 
10 STUDY DRUG(S) 
Dasatinib tablets are white to off-white , biconvex, film-coated tablets containing 
dasatinib, with the following inactive ingredients: la ctose monohydrate, 
microcrystalline cellulose, croscarme llose sodium, hydroxypropyl cellulose, and 
magnesium stearate. The tablet  coating consists of hyprome llose, titanium dioxide, and 
polyethylene glycol.  
10.1 Dasatinib Product Identification 
Dasatinib will be supplied in two different strengths by Bristol-Myers Squibb. 
 20 mg film-coated tablets, biconvex, r ound, white to off-white in appearance 
with“BMS” or “20” debossed on one side and "527" on the other side 
 50 mg film-coated tablets, biconvex, oval,  white to off-white in appearance 
with“BMS” or “50” debossed on one side and "528" on the other side 
 
10.2 Packaging and Labeling  
Dasatinib will be packaged in bottles as follows: 
 Dasatinib 20 mg film-coate d tablets, 30 tabs/bottle 
 dasatinib 50 mg film-coated tablets, 30 tabs/bottle 
Each bottle will be labeled in an open label.   Labels will contain, at a minimum, the 
following information: product name, tablet strength, batch number, directions for use, storage conditions, and appropr iate caution statements.
 
54 
 March 28, 2011
10.3 Storage, Handling and Dispensing of Dasatinib  
10.3.1 Storage 
10.3.2 
10
10
10Dasatinib tablets should be stored in a secure area at 25 C (77F); excursions permitted 
between 15°–30 C (59–86F). 
Handling and Disposal 
Procedures for proper handli ng and disposal of anticancer drugs should be considered. 
There is no general agreement that all of the procedures recommended in the guidelines 
are necessary or appropriate. 
Dasatinib tablets consist of a core tabl et (containing the active drug substance), 
surrounded by a film coating to prevent expos ure of pharmacy and clinical personnel to 
the active drug substance. However, if ta blets are crushed or broken, pharmacy and 
clinical personnel should w ear disposable chemothera py gloves. Personnel who are 
pregnant should avoid exposure to crushed and/or broken tablets.  
.3.3 Dispensing 
It is the responsibility of the Investigator to ensure that da satinib is only  dispensed to 
study subjects.  The dasatinib must be di spensed only from official study sites by 
authorized personnel accordi ng to local regulations. 
The Investigator (or assigned designee, i.e., study pharmacist ) will dispense the proper 
number of each strength tablet to the subject to satisfy dosing requirements for the 
study.  The containers provided to the subject should be labeled with proper instructions 
for use.  The lot numbers, dosing start dates and the number of tablets for each dosage strength must be recorded on the drug accountability pages of record for the site.  The subject must be instructed to return all unus ed dasatinib in the provided packaging at 
each subsequent visit. 
10.4 Drug Ordering and Accountability 
.4.1 Initial Orders 
Initial Orders of dasatinib will be requested by the assigned BMS protocol m
anager.  
Initial drug supply is provided for a 12-week treatment period per subject. 
.4.2 Re-supply 
Re-supply requests can be obtai ned by completing the SRC re-supply request form and 
submitting the request form electronically via e-mail to srcsupply@bms.com .  
Re-supply requests should be submitted at l east 5-7 business days before the expected 
delivery date.  Deliveries will be m
ade Tuesday through Friday. 
10.5 Dasatinib Accountability 
It is the responsibility of the Investigator to ensure that a current record of dasatinib 
disposition is maintained at each study site where dasatinib is inventoried and disposed.  
55 
 March 28, 2011
Records or logs must comply  with applicable regulations  and guidelines, and should 
include: 
 Amount received and placed in storage area.  
 Amount currently in storage area. 
 Label ID number or batch number  and use date or expiry date. 
 Dates and initials of person respons ible for each dasatinib inventory 
entry/movement. 
 Amount dispensed to and returned by each subject, including unique subject 
identifiers. 
 Amount transferred to another area /site for dispensing or storage. 
 Non-study disposition (e.g., lost, wasted, broken). 
 Amount returned to BMS, if applicable. 
 Amount destroyed at study site, if applicable. 
 Retain samples sent to third party for bioa vailability/bioequivale nce, if applicable. 
Dasatinib dispensing record/inventory logs and copies of signed packing lists must be 
maintained at the investigational site.  Batc h numbers for dasatinib must be recorded in 
the drug accountability records. 
10.6 Destruction of Dasatinib 
It is the Investigator’s responsibility to ensure that arrangements have been made for 
disposal and that procedures for proper disposal have been established according to 
applicable regulations, guideli nes, and institutiona l procedures.  Appropriate records of 
the disposal must be maintained.   
10.7 Zoledronic Acid 
10
10.7.2 Preparation .7.1 Supply 
Zoledronic acid will be purchased from No vartis in plastic vials containing 4mg 
zoledronic acid in a 5 mL concen trate as a solution for infusion.  
The zoledronic acid 4 mg/5 mL concentrate so lution is not for direct infusion and has to 
be further diluted prior to the use.  Prior to administration, the 5 mL of the concentrate 
solution must be diluted with 100 mL cal cium-free infusion solution (0.9% sodium 
chloride solution or 5% glucose solution).  The appropriate volume of the reconstituted 
zoledronic acid solution is 105 mL.  The n ecessary infusion bags/bottles, containing 
either 100ml calcium free 0.9% sodium chloride  or 5 % dextrose solution, that have to 
be used for the set up of the infusion will be  provided by the study center.  Glass bottles 
and infusion bags or tubing made from  polyvinylchloride (PVC), polypropylene (PP) 
and polyethylene (PE) are appropriat e for use with Zoledronic acid.  
56 
 March 28, 2011
If not used immediately after dilution with infusion media, for micr obiological integrity, 
the final solution must be placed in a refrig erator with a temperature between 2-8°C. 
The refrigerated solution should then be e quilibrated to room temperature prior to 
administration.   The total time between dilu tion, storage in a refr igerator, and end of 
administration of the infusion must not exceed  24 hours.  Reconstituted zoledronic acid 
solutions must be administered in no less than a 15-minute intravenous infusion in a line 
separate from all other drugs.  
A peripheral or central intrave nous site is to be used fo r the study drug infusion.  Study 
drug should  be administered as a single intr avenous solution in a line separate from all 
other drugs. The bore of the needle or angiocat heter used to insert the intravenous line 
will be 20 to 22 gauge.  The i.v. infusion will  be preceded by and followed by a 10 ml 
normal saline flush of the intravenous line.  In order to allow constant flow a vented 
infusion line should be used.  Prior to appl ication of the drug, th e infusion line via a y-
connector or other similar set-up will be flushed with approximately 10 ml of normal 
saline.  Thereafter, the solution will be in fused over a period of no less than 15 minutes. 
After emptying, approximately 3 mL of drug product solution may stay in the infusion 
bottle.  Use at least 10 ml of norma l saline to flush the infusion line. 
A pharmacist or other qualified person will be responsible for the preparation of the i.v.  
The qualified person who prepares the drug to  be infused must enter the appropriate 
drug preparation information requested on the sign off log for drug preparation.  Documentation of trial-drug administration and amount infused will be maintained for 
every patient 
Preparation of reduced dose solution for patients with mild to moderate renal 
impairment (CrCl <60 mL/min) at  baseline (baseline defined as  the serum creatinine, 
just prior to their first ever Zoledronic acid dose, approximately one year prior to 
study entry):  
Withdraw an appropriate volume of the 5 mL – study drug concentrate: 
 4.4 mL  for 3.5 mg dose 
 4.1 mL  for 3.3 mg dose 
3.8 mL  for 3.0 mg dose 
The withdrawn concentrate must be diluted in 100 mL of sterile 0.9% sodium chloride, 
USP, or 5% dextrose injection, USP. The dos e must be given as a single intravenous 
infusion over no less than 15 minutes. Medication vial labels will comply with th e legal requirements of the United States. 
They will supply no information about the patient, only the medication number. The 
storage conditions for stu dy drug will be described on the medication label. 
10.7.3 ANTICIPATED TOXICITY 
Anticipated toxicities are as described in the package insert for zoledronic acid (see 
Post-text supplement 2). 
57 
 March 28, 2011
10.7.3.1 Osteonecrosis of the Jaw (ONJ) 
After study entry, any patient report of the following symptoms at interim visits will 
require an examination by a dent al professional (dental hygienist  or dentist) to rule out 
ONJ prior to further study drug dosing: 
 exposed bone in the oral cavity 
 rough area on the jawbone 
 “heavy jaw”, a dull aching sensation 
 numbness/tingling of the jaw 
 loosening of teeth 
 tooth pain 
 sudden change in the health of periodontal or mucosal tissue 
 failure of oral mucosa to heal 
 undiagnosed oral pain,  
 soft tissue swelling, drainage or infection 
If exposed bone is observed on dental examination, the patient will be referred to an 
oral surgeon for a panoramic x-ray, diagnosis, and treatment.  While a precise definition 
of “ONJ” does not exist, Novartis has deve loped a working definition of ONJ based on 
input from a panel of experts.  Thus, an AE is designated as a possible case of ONJ if all the following criteria are met: 
1. There is exposed bone in the maxillofacial area that occurred either  
 spontaneously; or  
 was induced by dental surger y that has no evidence of healing for more than 
3 to 6 weeks after appropriate care 
2. May or may not be associated with infection 
3. May or may not be associated with pain 
4. Appeared in the absence of prior radiation to the head or neck 
If a diagnosis of ONJ is made, study me dication will be stopped permanently, the 
patient will be discontinued from the study, and further treatment will be at the 
discretion of the patient’s physician.  The pa tient will be followed for outcome of ONJ
. 
All such diagnosed cases of ONJ should be  considered as “medically significant,” 
irrespective of whether the ev ent meets the definition of “serious adverse event (SAE)” 
under current health authority guidelines.  These cases are therefore to be reported to 
Bristol-Myers Squibb as well as local health authorities under the guideline of SAE reporting (see section 11).     
Osteonecrosis at any skeletal site, and osteom yelitis at any skeletal site, should also be 
considered as medically significant and re ported to Bristol-Myers Squibb as well as 
local health authorities under the guid ance of SAE reporting (see Section 11) 
If diagnosis of ONJ is not  made, then the patient will be allowed to continue on the 
study at the discretion of the investigator. 
58 
 March 28, 2011
10.7.3.2 Monitoring of Renal Function 
Serum creatinine should be monitored in al l patients treated w ith zoledronic acid 
infusion prior to each dose. A 48-hour window  for checking creatinine is allowed prior 
to the each study infusion. Elevations in se rum creatinine above baseline values may 
require a delay in treatment.   
Each pre-infusion serum creatinine during the study must be compared with the baseline 
serum creatinine and should be managed as follows:   
 If the patient’s baseline serum creatinin e (before the first ever zoledronic acid 
dose) was < 1.4 mg/dL, an increase of 0.5  mg/dL or more will require that the 
study drug be delayed until the patient’s serum creatinine returns to no higher 
than 10% above the baseline value. 
 If the patient’s baseline (before the fi rst ever zoledronic acid dose) serum 
creatinine was ≥ 1.4 mg/dL, then an increase in  the serum creatinine of 1.0 
mg/dL or more will require that the study drug be delayed until the patients 
serum creatinine returns to no higher than 10% above the baseline value. 
 Any doubling of the baseline (before the fi rst ever zoledronic acid dose) serum 
creatinine will require that the study drug be delayed until the patient’s serum 
creatinine returns to no higher than 10% above the baseline value. 
Zoledronic acid should be re-initiated at the same dose as that prior to treatment 
interruption.  
11 ADVERSE EVENTS  
An Adverse Event (AE) is defined as any untoward medical occurrence in a patient or 
clinical investigati on subject administered  a pharmaceutical pr oduct and that does not 
necessarily have to have a ca usal relationship with this tr eatment. An AE can therefore 
be any unfavorable and unintended sign (i ncluding an abnormal laboratory finding), 
symptom, or disease temporally associated with the use of dasatinib whether or not 
considered related to dasatinib. 
During clinical trials, advers e events can be spontaneously  reported or elicited during 
open-ended questioning, examin ation, or evaluation of a subject. (In order to prevent 
reporting bias, subjects should not  be questioned regarding th e specific occurrence of 
one or more adverse events.) A serious AE is any untoward medical occurrence that at any dose
:   
 results in death,  
 is life-threatening (defined as an event in which the patient was at risk of death at 
the time of the event; it does not refer to  an event which hypothetically might have 
caused death if it were more severe),  
 requires inpatient hospitalization or causes prolongation of exis ting hospitalization,  
 results in persistent or significant disability/incapacity,  
 is a congenital anomaly/birth defect,  
59 
 March 28, 2011
 results in the development of drug dependency or drug abuse,  
 is an important medical event (defined as a medical event(s) that may not be 
immediately life-threatening or result in death or hospi talization but, based upon 
appropriate medical and scie ntific judgment, may jeopa rdize the patient or may 
require intervention (e.g., medical, surgical ) to prevent one of the other serious 
outcomes listed in the definition above.)  Examples of such events include, but are not limited to, intensive treatment in an emergency room or at home for allergic 
bronchospasm; blood dyscrasias or convulsions that do not result in 
hospitalization.) For reporting purposes, also consider the occurrences of 
pregnancy or overdose (regardless of ad verse outcome) as events which must 
be reported as important medical events.  
11.1 Reporting of SAEs 
Following the subject’s written consent to participate in the study, all SAEs should be collected and reported, including those thought to be as sociated with clinical trial 
procedures. Following study completion, any SAE thought to be relate d to study drug or 
clinical trial proce dures should also be reported to BMS. 
SAE terminology and severity grading will be based on NCI Common Toxicity 
Criteria (CTC) Scale, version 3.0.  
The following categories and definitions of causal relationship to study drug should be considered for use for all clin ical studies supported by BMS: 
 Certain: There is a known causal relations hip between the study drug and the SAE. 
The event responds to wit hdrawal of study drug (dechal lenge), and recurs with 
rechallenge when clinically feasible. (>95% certainty) 
 Probable: There is reasonable causal re lationship between the study drug and the 
SAE. The event responds to dechallenge. Rechallenge is not required. (65%-95% 
probability) 
 Possible: There is reasonable causal re lationship between the study drug and the 
SAE. Dechallenge information is lacki ng or unclear. (35%-65% probability of 
relatedness) 
 Not likely: There is temporal  relationship to study drug ad ministration, but there is 
not a reasonable causal relationship betw een the study drug and the SAE. (5-35% 
probability of relatedness) 
 Not related: There is not a temporal relationship to study drug administration (too 
early, or late, or study drug not taken), or there is known causal relationship 
between the SAE and another drug, concurrent  disease, or other circumstance. (<5% 
chance of relatedness) 
 Adverse events classified as “serious” re quire expeditious hand ling and reporting to 
BMS to comply with regulatory requirements.  
 All SAEs whether related or unrelated to dasatinib, must be imme diately reported to 
BMS (by the investigator or  designee) within 24 hours of becoming aware of the 
event.  If only limited information is initially available, follow-up reports are required.  The original SAE form must be kept on file at the study site. 
60 
 March 28, 2011
 All SAEs should be faxed or em ailed to Bristol-Myers Squibb at: 
Global Pharmacovigilance & Epidemiology 
Bristol-Myers Squibb Company Fax Number:  609-818-3804 Email: Worldwide.safety@bms.com  
 For studies conducted under an Investigator IND
, any event that is both serious and 
unexpected must be reported to the FDA as soon as possibl e and, in no event, later 
than 7 days (death or life-threatening even t) or 15 days (all other SAEs) after the 
investigator’s or institution’ s initial receipt of the information.  Bristol-Myers 
Squibb will be provided with  a simultaneous copy of all adverse events filed with 
the FDA.  SAEs should be reported on the MedWatch Form 3500A, which can be 
accessed at: http://www.accessdata.fda.gov/scripts/medwatch/  
MedWatch SAE forms should be sent to the FDA at: 
MEDWATCH  
5600 Fishers Lane 
Rockville, MD  20852-9787 Fax:  1-800-FDA-0178 (1-800-332-0178) http://www.accessdata.fda.gov/scripts/medwatch/  
 
All SAEs should simultaneously be faxed or e-mailed to Bristol-Myers Squibb at: 
Global Pharmacovigilance & Epidemiology 
Bristol-Myers Squibb Company Fax Number:  609-818-3804 Email: Worldwide.safety@bms.com  
 Collection of complete information concerni ng SAEs is extremely important.  Full 
descriptions of each event will be followed by BMS. Thus, follow-up information which becomes available as the SAE evolves, as  well as supporting documentation (e.g., 
hospital discharge summaries and autopsy repo rts), should be collected subsequently, if 
not available at the time of the initial re port, and immediately sent using the same 
procedure as the initial SAE report. 
 An overdose is defined as the accidental or intentional ingestion of  any dose of a product 
that is considered both excessive and medi cally important.  For reporting purposes, BMS 
considers an overdose, regardless of advers e outcome, as an important medical event.  
 AEs should be followed to resolution or stab ilization, and reported as SAEs if they 
become serious. This also appl ies to subjects experiencing AE s that cause interruption or 
discontinuation of dasatinib, or those experiencing AEs that are present at the end of their 
participation in the study; such subjects should receive post-treatment follow-up as appropriate.  
 In BMS supported trials, all SAEs must be collected which occur within 30 days of 
discontinuation of dosing or completion of the patient’s participation in the study if the 
last scheduled visit occurs at a later time.  In addition, the Investigator should notify BMS 
61 
 March 28, 2011
of any SAE that may occur after this time pe riod which they believe to be certainly, 
probably, or possibly related to dasatinib. 
 
12 STATISTICAL METHODOLOGY 
12.1 PHASE I 
The primary objective of the phase I portion of this trial will be to determine the RP2D 
for dasatinib in combinati on with zoledronic acid.  
 
The phase I portion of the trial will use a 3+ 3 dose escalation design. If at least 2 of 3 
patients treated within a gi ven dosing cohort develop DLT,  it can be concluded with 
90% confidence that the true probability of DLT at that dose is greater than 20%. If 
none of the 3 patients demonstrates DLT, it can  be concluded with 90% confidence that 
the true probability of DLT is less than 55 %. These criteria are considered a standard 
for dose selection using the proposed  phase I clinical  trial design.  
 When 1 of 3 patients develops DLT and the cohort is expanded to 6 patients, the proposed plan for dose escalation provides 91% probability that dose escalation will not 
be stopped at doses associat ed with DLT probability of < 10% and gives a 92% 
probability that escalation will not pro ceed beyond doses associated with DLT 
probability in excess of 60%. The stepwise dose escalation also protects against defining an RP2D associated w ith excessive toxicity. For a wi de variety of dose-toxicity 
curves, the probability is approximately 85-90% that the defined RP2D will be associated with DLT probability of approximately 10-45%.  
12.2 
 Phase II  
The primary objective of this phase II study is to assess the efficacy of dasatinib in 
combination with zoledronic acid.  Up to 25 patients will be enrolled in the phase II 
study to assess the efficacy of dasatinib in combination with zometa (zoledronic acid).  
The primary endpoint is the response rate.  The trial will be c onducted by the Simon’s 
two-stage design using the minimax criterion and the response rate  will be estimated 
accordingly.  It is assumed that dasatinib in combination with zometa will have a target response rate 
of 25%.  A response rate of  5% or lower is considered a failure.  When the probability 
of accepting a “bad” regimen (i.e. response rate  5%) is 0.05 and the probability of 
rejecting a “good” regime n (i.e. response rate  25%) is  0.10, Simon’s design to 
minimize the maximum sample size requires 15 pa tients in the first stage.  If no patients 
respond to the treatment, the trial will be stopped and the regimen will be declared as ineffective.  If at least on e of the first 15 patients respond to the treatment, 10 additional 
patients will be entered in the study to reach a total of 25 patients.  By the end of the 
study, the new regimen will be rejected if response  rate is less than or equal to 3 out of 
25 patients and will be accepted otherwise.  Th e operating characteristics of the trial are 
62 
 March 28, 2011
given as follows.  When th e true response rate is 0.05, the probability of stopping the 
trial early is 46.3%.  On the other hand, if the true response rate is 0.25, the probability 
to stop the trial early is 1 .3%.  The expected sample sizes are 20.37 and 24.97 when the 
true response rates are 0.05 and 0.25, respectively.  At the end of the study, the response 
rate and the 95% confidence interval will be  reported and the toxicity profile of the 
regimen will be summarized.  If the trial continues to the second stage (i.e., accrual = 
25) and the 5 of 25 patients response for a point estimate of 20.0%, the exact binomial 
95% confidence interval would be (6.8%, 40.7%).    
Patients will be divided into two cohorts dependent upon Ntx levels obtained prior to 
the initiation of therapy. All patients will receive same th erapy, lab draws and 
radiographic assessment for response.  
12.2.1 
12.2.2 Cohort A: Patients with moderate or high baseline 
levels of Ntx: 
We will determine the association between ch anges in Ntx levels and tumor response, 
progression-free survival (PFS), and overall survival (OS).  
 
Changes in Ntx levels will be considered as both a continuous and a dichotomous measure.  
We will describe the percent change and the abso lute change in Ntx levels from baseline to 
one month and from baseline to 3 months following the start of treatment with descriptive 
statistics such as the mean, median, range, and st andard deviation.  We will use the t-test or 
Wilcoxon’s rank sum test to determine the asso ciation between changes in Ntx levels and 
tumor response.  Considering the change in Ntx levels as dichotomous (maintained moderate or high level versus achieved low level) we will determine the association between achieving 
a low Ntx level and tumor response with a chi-squa re or Fisher’s exact test as appropriate.   
PFS will be measured from the date of fi rst treatment to th e date of disease 
progression or death from any cause.  OS w ill be measured from the date of first 
treatment to the date of death from any cau se.  The percent change and the absolute 
change in Ntx levels will be included in Cox proportional hazards models to estimate 
the change in the hazard of death and th e change in the haza rd of progression 
associated with a change in Ntx levels.  Considering the change in Ntx levels as 
dichotomous, the Kaplan-Meier product limit method will be used to estimate PFS and OS and the log-rank statistic will be used  to test for differenc es between patients 
who do and do not achieve a low level Ntx level.  Finally, we will consider the serial measurements of Ntx by including them as a time-dependent covariate in Cox 
proportional hazards models.   
 
 Cohort B: Patients  with low  levels of Ntx: 
 
These patients have been reported to have a mo re favorable outcome compared to patients 
with moderate to high levels. However, it remain s uncertain if further reduction of Ntx levels 
in this subset of patients would be predictive of response to therapy.   
63 
 March 28, 2011
We will first describe the percent change and absolute change in Ntx levels from baseline to 
one month and from baseline to three months following the start of treatment with descriptive statistics such as th e mean, median, range, and standard deviation.  Percent 
change in Ntx will also be considered as a dichotomous measure usi ng 30% as the threshold 
value.  We will describe both the change in Ntx levels and the proportion of patients with at least a 30% decrease in Ntx levels separately  by tumor response groups.  We will plot the 
Kaplan-Meier curves of PFS and OS overall su rvival and visually assess the differences 
between patients who achieved at least a 30% decrease in Ntx and those who did not.   
 
13 ADMINISTRATIVE SECTION 
13.1 Compliance with the Protocol and Protocol Revisions 
The study must be conducted as described in the final approved protocol.  All revisions 
to the protocol must be pr ovided to BMS along with IRB approval verification.  The 
Investigator should not implement any deviatio n or change to the pr otocol without prior 
review and documented approval/favorable opinion from the IRB of an Amendment, 
except where necessary to eliminate an immediate hazard(s) to study patients. 
 Documentation of approval signed by the chairp erson or designee of the IRB(s) must be 
sent to BMS. 
13.2 Ethical Considerations and Informed Consent 
The following must be observed in order to comply with Food and Drug Administration 
regulations for the conduct and mon itoring of clinical  investigations: 
 
The principles of informed consent are described by Federal Regulatory Guidelines. 
13.3 Records and Reports 
An Investigator is required to prepare and maintain adequate and accurate case histories 
designed to record all observat ions and other data pertinent to the investigation on each 
individual treated with th e investigational product.  
13.4 Institutional Review Board (IRB) 
Before study initiation, the I nvestigator must have writte n and dated approval/favorable 
opinion from the IRB for the protocol , consent form, patient recruitment 
materials/process (e.g., advertisements), and any other written information to be 
provided to patients.  The Investigator shou ld also provide the IRB with a copy of the 
product labeling, information to be pr ovided to patients, and any updates. 
 
The Investigator will provid e the IRB with reports, updates,  and other information (e.g., 
Safety Updates, Amendments, Administ rative Letters) according to regulatory 
requirements and Institution procedures.  
64 
 March 28, 2011
A detailed list of required regulatory docum ents also to be submitted to BMS will be 
sent upon final approval of the protocol.  
13.5 Records Retention 
The Investigator must retain investigati onal product disposition records, case report 
forms and source documents for the maximum period required by applicable regulations 
and guidelines, or In stitution procedures. 
 
If the Investigator withdraws from the study  (e.g., relocation, reti rement), the records 
shall be transferred to a mutually agr eed upon designee (e.g., another Investigator, 
IRB). Notice of such transfer will be given in writing to BMS. 
14 CORRELATIVE STUDIES 
14.1 Biologic Characterization of Response Using 18F-FDG 
PET: 
Characterization of response using PET will be performed through collaboration with 
Dr. Juri Gelovani, chair of the Department of Experimental Diagnostic Imaging in the 
Division of Diagnostic Imaging at MDACC. 18F-FDG PET imaging has demonstrated 
increased glucose consumption in breast can cer with substantial variation in uptake 
influenced by the number of viable tumor ce lls per volume, histological subtype (ductal 
> lobular), tumor grade, microvessel density and proliferative activ ity(35). In addition, 
changes in 18F-FDG PET avidity have been correla ted with breast cancer response to 
both hormonal therapy and chemotherapy an d in patients with predominate bone 
metastasis in small non-randomized studies (36-38). Although FDG uptake has been 
studied in patients with solid tumors treated with the angiogenesis i nhibitors(39), to date 
no published phase II data ex ists concerning changes in 18F-FDG  uptake in breast 
cancer patients treated with dasatinib. It is  hypothesized that dasa tinib’s inhibition of 
the paracrine loop supporting bone metastasis will result in decreased cancer cell proliferation, decreased microvessel density and a decrease in the number of viable 
tumor cells, which will decrease tumor avidity for
18F-FDG.  MDACC has had extensive 
experience with the use of PET to image intrac ellular receptors, such as ER, in breast 
cancer patients(40) and in the development of biologic marker s of response in patients 
undergoing therapy with angi ogenesis inhibitors(39).  
Patients who consent to participate will undergo optional 18F-FDG PET imaging at 
baseline, between days 12-16 of therapy (2 week value), and at disease progression.  
The fold change from baseline will be calculated for the 2 week value and progression of disease value. These values will then be graphed using scatterplo ts against urine Ntx 
to assess the relationship of response to th is biologic endpoint.  In addition, it is known 
that variations in 
18F-FDG PET avidity can occur within different foci of disease in 
individual patients. These variations ma y represent biologic differences between 
responding and non-responding cells; therefore, core needle biopsies will be performed 
on a subset of patients who consent to biopsy of > 2 sites of metastatic tumors that differ 
in 18F-FDG PET uptake (see Molecular Correlates below). 
65 
 March 28, 2011
14.2  Determination of Molecular Correlates in Paraffin 
Embedded or Frozen Tissue: 
Tumor biopsies will be obtained by imagi ng (CT or Ultrasound) guided core needle 
biopsy from patients who sign informed consent for tissue biopsy. Biopsies will be 
obtained at pre-treatment and at day 28 of cycle 1 (+/- 48 hours). Dasatinib inhibits a 
number of targets including SRC, PDGFR, c-kit, FAK and EPHA2. Expression of these 
markers may be correlated with tumor respon se and their expression  in bone metastasis 
remains ill defined. Tumor samples will be analyzed for these targets using 
immunohitochemistry.  In addition, Src regulates  proteins such as cavelolin and STAT3, 
which are responsible for oste oblastic activity, tumor cell me tastasis and migration, and 
response to chemotherapy (41) (42),(7). We  will also use immunohistochemistry to 
measure phosphorylated activity of these protei ns in pre- and post- treatment biopsies to 
determine the biologic effects of therapy. In addition, as stipulated in the biologic 
rationale for this study, Src has been linke d to angiogenesis through downstream effects 
on STAT3(43, 44). We will therefore measure the effects of dasatinib on  VEGF and 
IL-8 using immunohistochemistry in pr e- and post-treatment samples. 
 Fresh tissue obtained by core needle biopsy of  metastatic sites differing in PET avidity 
in individual patients (see above) will be snap frozen and used for microarray analysis to determine potential pathways of drug resist ance. When possible, these results will be 
confirmed using IHC, western blotting or PCR. 
 
14.3 Banking of Blood Samples 
Patients will be asked to donate 10cc of res earch blood pretreatment and on day 28 (+/- 
48 hours) of weeks 4, 8, 16, and 24. Research bl ood will also be collected at the time of 
disease progression.  Serum w ill be banked for future treatment efficacy analyses 
including potential markers of bone turnover. (cycle = 28 days/4 weeks) 
 
The following protocol will be followed:  
 
1) Subject should be seated for at least five minutes prior to blood collection.  The 
draw should be from the median cubital, cepha lic, or basilic veins.  If possible, the 
draws should be dedicated draws to collect these samples.   
 
2) Using approved, standardized methods and supplies, trained phlebotomists will 
collect one 3cc priming discard  blood sample. Then collect one 10 cc test sample from 
each donor into labeled blood collection tube s without anticoagulant (red top). Tubes 
must be completely filled.   3) Allow the blood to clot for 30 minutes to 1 hour at room temperature.   4) Pipette the serum off of the clot and place into a clean test tube. Clarify by 
centrifugation at 3000 rpm for 15 minutes. Ca refully remove the stopper tops and 
66 
 March 28, 2011
67 using a transfer pipette transfer the serum from the red top tube into 500 uL aliquot 
vials.   
 5) Enter the number of vials and the sa mple information into the Freezerworks 
database.  
 
6) Store serum samples in -80 C freezer. 
Patients confidentiality will be guarantee d. The information gathered from each 
individual patient will be used as part of a larger statistical analysis. Patients will not be 
harmed because data from individual patients will be coded. The samples will be coded using consecutive numbers (1, 2, 3, etc).  A c ode breaker exists in the possession of the 
principal investigator. The c ode breaker can be used to match the coded specimens to 
the specimen source (i.e., pretreatment, pos t treatment). To minimize any potential 
breaches of confidentiality, specimens are stored in a secure freezer in the laboratory of Dr. Francisco Esteva at MDACC. Participan ts’ data will be stor ed in the principal 
investigator’s computer, which is password protected. 
Banked samples will be available to future investigators at the discretion of the 
Principal Investigator and only for us e through MDACC IRB a pproved protocols. 
  Samples will be shipped to: 
 Stacy Moulder, M.D., M.S.C.I. 
 The University of Texas M.D. Anderson Cancer Center 
 Department of Breast Medical Oncology, Unit 1354 
                          1155 Herman P. Pressler, CPB5.3450 
                          Houston, TX  77030-3721 
 March 28, 2011
68 REFERENCES 
1. Roodman GD. Mechanisms of bone me tastasis. N Engl J Med 2004;350: 1655-64. 
2. Coleman RE, Rubens RD. Bone metastases and breast cancer. Cancer  Treat Rev 1985;12: 251-
70. 
3. Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Bone imaging in 
metastatic breast cancer. J Clin Oncol 2004;22: 2942-53. 
4. Verbeek BS, Vroom TM, Adriaansen-Slot SS , et al.  c-Src protein expression is increased in 
human breast cancer. An immunohistochemical and biochemical analysis. J Pathol 1996;180: 383-8. 
5. Belsches-Jablonski AP, Biscardi JS, Peavy DR, Tice DA, Romney DA, Parsons SJ. Src family 
kinases and HER2 interactions in human breast cancer cell growth and survival. Oncogene 2001;20: 1465-75. 
6. Madan R, Smolkin MB, Cocker R, Fayyad R, Oktay MH. Focal adhesion proteins as markers 
of malignant transformation and prognostic indicators in breast car cinoma. Hum Pathol 2006;37: 9-15. 
7. Diaz N, Minton S, Cox C , et al. Activation of stat3 in primary tumors from high-risk breast 
cancer patients is associated with elevated leve ls of activated SRC and survivin expression. Clin 
Cancer Res 2006;12: 20-8. 8. Gritsko T, Williams A, Turkson J , et al. Persistent activa tion of stat3 signali ng induces survivin 
gene expression and confers resist ance to apoptosis in human breast cancer cells. Clin Cancer Res 
2006;12: 11-9. 9. Myoui A, Nishimura R, Williams PJ, et al.  C-SRC tyrosine kinase activity is associated with 
tumor colonization in bone and lung in an animal  model of human breast cancer metastasis. Cancer 
Res 2003;63: 5028-33. 10. Horne WC, Neff L, Chatterjee D, Lomri A, Levy JB, Baron R. Osteoclasts express high levels 
of pp60c-src in association with intracellu lar membranes. J Cell Biol 1992;119: 1003-13. 
11. Missbach M, Jeschke M, Feyen J , et al.  A novel inhibitor of the tyro sine kinase Src suppresses 
phosphorylation of its major cellular substrates and reduces bone reso rption in vitro and in rodent 
models in vivo. Bone 1999;24: 437-49. 
12. Lev DC, Kim SJ, Onn A , et al. Inhibition of platelet-derived growth factor receptor signaling 
restricts the growth of human breast cancer in the bone of nude mi ce. Clin Cancer Res 2005;11: 306-
14. 13. Yi B, Williams PJ, Niewolna M, Wang Y, Yone da T. Tumor-derived pl atelet-derived growth 
factor-BB plays a critical role in osteosclerotic bone metastasis  in an animal model of human breast 
cancer. Cancer Res 2002;62: 917-23. 14. SPRYCEL® (dasatinib) Tablets Prescribing In formation.  Bristol-Myers Squibb Company P, 
NJ. June 2006. 15. SPRYCELÒ (dasatinib) BMS-354825 B-MSIB, Version #5, 2006. 
 March 28, 2011
69 16. Berenson JR, Rosen LS, Howell A , et al. Zoledronic acid reduces skeletal-related events in 
patients with osteolytic meta stases. Cancer 2001;91: 1191-200. 
17. Rosen LS, Gordon DH, Dugan W, Jr. , et al.  Zoledronic acid is superior  to pamidronate for the 
treatment of bone metastases in breast carcinoma patients with at le ast one osteolytic lesion. Cancer 
2004;100: 36-43. 
18. Saad F, Gleason DM, Murray R , et al.  A randomized, placebo-controlled trial of zoledronic 
acid in patients with hormone-refr actory metastatic prostate carc inoma. J Natl Cancer Inst 2002;94: 
1458-68. 
19. Rosen LS, Gordon D, Tchekmedyian S , et al. Zoledronic acid versus placebo in the treatment 
of skeletal metastases in patie nts with lung cancer and other solid  tumors: a phase III, double-blind, 
randomized trial--the Zoledronic Acid Lung Cancer and Other Solid Tumors Study Group. J Clin 
Oncol 2003;21: 3150-7. 
20. Varricchio L, Migliaccio A, Castoria G , et al. Inhibition of estradiol receptor/Src association 
and cell growth by an estradiol receptor alpha ty rosine-phosphorylated peptide. Mol Cancer Res 
2007;5: 1213-21. 21. Fox EM, Bernaciak TM, Wen J, Weaver AM, Shupnik MA, Silva CM. STAT5b, c-Src, and 
EGFR Signaling Play Integral Ro les in Estrogen-Stimulated Proliferation of ER-Positive Breast 
Cancer Cells. Molecular endoc rinology (Baltimore, Md 2008. 
22. Saad F, Gleason DM, Murray R , et al.  Long-term efficacy of zoledronic acid for the prevention 
of skeletal complications in patients with metasta tic hormone-refractory prosta te cancer. J Natl Cancer 
Inst 2004;96: 879-82. 
23. Rosen LS, Gordon D, Tchekmedyian NS , et al.  Long-term efficacy and safety of zoledronic 
acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other 
solid tumors: a randomized, Phase III, double-blind, placebo-controlled trial. Cancer 2004;100: 2613-
21. 24. Rosen LS, Gordon D, Kaminski M , et al. Long-term efficacy and safety of zoledronic acid 
compared with pamidronate disodium in the treatment of skeletal complications in patients with 
advanced multiple myeloma or breast carcinoma: a randomized, double-blind, multicenter, comparative trial. Cancer 2003;98: 1735-44. 
25. Coleman RE, Major P, Lipton A , et al.  Predictive value of bone  resorption and formation 
markers in cancer patients with bone metastases receiving the bisphosphonate zoledronic acid. J Clin 
Oncol 2005;23: 4925-35. 26. Reszka AA, Halasy-Nagy JM, Masarachia PJ, Rodan GA. Bisphosphonates act directly on the 
osteoclast to induce casp ase cleavage of mst1 kinase during apoptosis. A link between inhibition of the 
mevalonate pathway and regulation of an apoptos is-promoting kinase. The Journal of biological 
chemistry 1999;274: 34967-73. 
27. Bezzi M, Hasmim M, Bieler G, Dormond O, Ru egg C. Zoledronate sensitizes endothelial cells 
to tumor necrosis factor-induced programmed cell death: evidence for the suppression of sustained 
activation of focal adhesion kinase and protein ki nase B/Akt. The Journal of biological chemistry 
2003;278: 43603-14. 
 March 28, 2011
70 28. Brown JE, Cook RJ, Major P , et al.  Bone turnover markers as  predictors of skeletal 
complications in prostate cancer,  lung cancer, and other solid tumors. J Natl Cancer Inst 2005;97: 59-
69. 
29. Vinholes J, Coleman R, Lacombe D , et al.  Assessment of bone response to systemic therapy in 
an EORTC trial: preliminary experience with the use of collagen cross-link excretion. European 
Organization for Research and Treatmen t of Cancer. Br J Cancer 1999;80: 221-8. 
30. Brown JE, Thomson CS, Ellis SP, Gutcher SA , Purohit OP, Coleman RE. Bone resorption 
predicts for skeletal complications  in metastatic bone disease. Br itish journal of cancer 2003;89: 2031-
7. 31. Costa L, Demers LM, Gouveia-Oliveira A , et al.  Prospective evaluation of the peptide-bound 
collagen type I cross-links N-telopeptide and C-telope ptide in predicting bone me tastases status. J Clin 
Oncol 2002;20: 850-6. 32. Lipton A, Demers L, Curley E , et al.  Markers of bone resorption in patients treated with 
pamidronate. Eur J Cancer 1998;34: 2021-6. 33. Clemons M, Cole DE, Gainford MC. Can bone ma rkers guide more effective treatment of bone 
metastases from breast cancer? Breast can cer research and treatment 2006;97: 81-90. 
34. Thall PF, Simon R. A Bayesian approach to esta blishing sample size and monitoring criteria for 
phase II clinical trials. Cont rol Clin Trials 1994;15: 463-81. 
35. Avril N, Menzel M, Dose J , et al.  Glucose metabolism of brea st cancer assessed by 18F-FDG 
PET: histologic and immunohistochemical tissue analysis . J Nucl Med 2001;42: 9-16. 
36. Mankoff DA, Dunnwald LK, Gralow JR , et al. Blood flow and metabolism in locally advanced 
breast cancer: relationship to response to therapy. J Nucl Med 2002;43: 500-9. 
37. Mortimer JE, Dehdashti F, Siegel BA, Kat zenellenbogen JA, Fracasso P, Welch MJ. Positron 
emission tomography with 2-[18F]Fluoro-2-de oxy-D-glucose and 16alpha-[18F]fluoro-17beta-
estradiol in breast cancer: correlat ion with estrogen receptor status and response to systemic therapy. 
Clin Cancer Res 1996;2: 933-9. 38. Stafford SE, Gralow JR, Schubert EK , et al. Use of serial FDG PET to measure the response of 
bone-dominant breast cancer to th erapy. Acad Radiol 2002;9: 913-21. 
39. Herbst RS, Mullani NA, Davis DW , et al. Development of biologic markers of response and 
assessment of antiangiogenic activity in a clinical trial of human recombinant endostatin. J Clin Oncol 
2002;20: 3804-14. 
40. Inoue T, Kim EE, Wallace S , et al.  Positron emission tomography using [18F]fluorotamoxifen 
to evaluate therapeutic responses  in patients with breast cancer: preliminary study. Cancer Biother 
Radiopharm 1996;11: 235-45. 41. Sloan EK, Stanley KL, Anderson RL. Caveolin-1 inhibits breast cancer growth and metastasis. 
Oncogene 2004;23: 7893-7. 42. Cantiani L, Manara MC, Zucchini C , et al.  Caveolin-1 reduces osteosarcoma metastases by 
inhibiting c-Src activity and met signa ling. Cancer research 2007;67: 7675-85. 
 March 28, 2011
71 43. Trevino JG, Gray MJ, Nawrocki ST, et al. Src activation of Stat 3 is an independent 
requirement from NF-kappaB activation for const itutive IL-8 expression in human pancreatic 
adenocarcinoma cells. A ngiogenesis 2006;9: 101-10. 
44. Gray MJ, Zhang J, Ellis LM , et al. HIF-1alpha, STAT3, CBP /p300 and Ref-1/APE are 
components of a transcriptional complex that regu lates Src-dependent hypoxia- induced expression of 
VEGF in pancreatic and prostate carcinomas. Oncogene 2005;24: 3110-20. 
45. Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi  GN, Ueno NT. Bone imaging in metastatic 
breast cancer. J Clin Oncol 2004;22: 2942-53. 
  
  
 March 28, 2011
72 Post-Text Supplement 1 (See attached Dasatinib Investigator’s Brochure) 
Post-Text Supplement 2 (See attached Zometa (Zoledronic Acid) Package 
Insert) 
Post-Text Supplement 3: RECIST Criteria 
 Solid Tumor Response Criteria (RECIST)   
Malignant Disease Evaluation   
To assess objective response, it is necessary to estimate the overall 
tumor burden at baseline to whic h subsequent measurements will be 
compared. Measurable dise ase is defined by the presence of at least 
one measurable lesion. 
All measurements should be recorded in metric notation by use of a 
ruler or calipers. The same me thod of assessment and the same 
technique should be used to characterize each identified lesion at 
baseline and during follow-up. All baseline evaluations should be 
performed as closely as possible to  the beginning of treatment and 
never more than four weeks  before registration. 
The term evaluable in reference to measurability will not be used because it does not provide add itional meaning or accuracy. 
At baseline, tumor lesions will be char acterized as either measurable or 
non-measurable. 
Measurable
  
Lesions that can be accurately measured in at least one dimension (longest diameter to be recorded) as > 20 mm (2.0 cm) with conventional te chniques or as > 10 mm (1.0 
cm) with spiral CT scan. 
If the measurable disease is rest ricted to a solitary lesion, its 
neoplastic nature should be confi rmed by cytology/histology. 
Non-Measurable
  
All other lesions, including smal l lesions [longest diameter < 
20 mm (2.0 cm) with conventional techniques or < 10 mm 
(1.0 cm) with spiral CT sc an] and truly non-measurable 
lesions. 
Lesions considered to be trul y non-measurable include the 
following: bone lesions, leptomeningeal disease, ascites, 
pleural/pericardial effusion, inflammatory breast disease, 
lymphangitis cutis/pulmonis, abdominal masses that are not 
 March 28, 2011
73 confirmed and followed by im aging techniques, and cystic 
lesions. 
Definitions of Response   
Target Lesions   
All measurable lesions up to a maximum of five lesions per 
organ and 10 lesions in total, r epresentative of all involved 
organs. Target lesions should be  selected on the basis of 
their size (those with the lo ngest diameters) and their 
suitability for accurate  repeated measurements. 
The sum of the longest diameters of all target lesions will be 
calculated at baseline and reported as the bas eline sum 
longest diameter . The sum longest diameter  will be used to 
characterize the objective tumor response. For lesions 
measurable in 2 or 3 dimensio ns, always report the longest 
diameter at the time of each assessment. 
Complete Response (CR)   
The disappearance of all target  lesions. To be assigned a 
status of complete response, changes in tumor measurements must be confi rmed by repeat assessments 
performed no less than four weeks  after the criteria for 
response are first met. 
Partial Response (PR)
  
At least a 30% decrease in the sum of the longest diameters 
of target lesions, taking as reference the baseline sum 
longest diameter. To be assigned a status of partial response, changes in tumor measurements must be confirmed by repeat assessments performed no less than 
four weeks  after the criteria for response are first met. 
Progressive Disease (PD)
   
At least a 20% increase in t he sum of the longest diameters 
of target lesions, taking as reference the smallest sum 
longest diameter  recorded since the baseline measurements, 
or the appearance of one or more new lesion(s). 
Stable Disease (SD)   
Neither sufficient shrinkage to qualify for partial response nor sufficient increase to qualify for progressive disease. To be 
assigned a status of stable disease, measurements must 
have met the stable disease criter ia at least once after study 
entry at a minimum interval of eight weeks. 
 March 28, 2011
74 Nontarget Lesions   
All other lesions or sites of diseas e. Measurements of these lesions are 
not required, but the presence or absence of each should be noted 
throughout follow-up. 
Complete Response (CR)   
The disappearance of all nontar get lesions and normalization 
of tumor marker levels, if applicable. To be assigned a status 
of complete response, changes in tumor measurements must 
be confirmed by repeat assessments performed no less 
than four weeks after the criteria for response are first met. 
Incomplete Response/Stable Disease (SD)   
The persistence of one or more nontarget lesion(s) and/ or 
the maintenance of tumor mark er levels above the normal 
limits. To be assigned a status of stable disease, 
measurements must have met the stable disease criteria at 
least once after study entry at a minimum interval of eight 
weeks.  
Progressive Disease (PD)   
The appearance of one or mo re new lesion(s) and/or 
unequivocal progression of existing nontarget lesions. 
Symptomatic Deterioration   
Patients with a global deteriorati on of health status requiring 
discontinuation of treat ment without objective evidence of disease 
progression at that time should be classified as having symptomatic 
deterioration. 
Evaluation of Patient's Best Overall Response   
The best overall response is the best resp onse recorded from registration until 
disease progression/recurrence, taking as reference for progressive disease the 
smallest measurements recorded since r egistration. The table below provides 
overall responses for all po ssible combinations of tumo r responses in target and 
nontarget lesions, with or without new lesions. 
To be assigned a status of complete or  partial response, changes in tumor 
measurements must be confirmed by  repeat assessments performed no less 
than four weeks after the criteria for response are first met. 
To be assigned a status of stable dis ease, measurements must have met the 
stable disease criteria at least once after study entry at a minimum interval of 
eight weeks. 
Overall Response for all Possible Combinations of Tumor Response 
 March 28, 2011
75 Target 
Lesions Nontarget Lesions New Lesions Overall Response 
CR CR No CR 
CR Incomplete 
response/SD No PR 
PR Non-PD No PR 
SD Non-PD No SD 
PD Any Yes or No PD 
Any PD Yes or No PD 
Any Any Yes PD 
CR = complete response; PR = partial response; SD = stable disease; PD = 
progressive disease 
First Documentation of Response   
The time between initiation of therapy and first documentation of PR or 
CR. 
Confirmation of Response   
To be assigned a status of complete  or partial response, changes in 
tumor measurements must be conf irmed by repeat assessments 
performed no less than four weeks after the criteria for response are 
first met. 
Duration of Response   
Duration of overall response – the per iod measured from the time that 
measurement criteria are met fo r complete or partial response 
(whichever status is recorded first) until the first date that recurrent or progressive disease is objectively documented, taking as reference the 
smallest measurements recor ded since treatment started. 
Duration of Overall Complete Response
  
The period measured from the ti me measurement criteria are 
met for complete response until t he first date that recurrent 
disease is objectively documented. 
Duration of Stable Disease   
A measurement from r egistration until the criteria for disease 
progression is met, taking as reference the smallest measurements recorded since r egistration. To be assigned a 
status of stable disease, m easurements must have met the 
stable disease criteria at leas t once after study entry at a 
minimum interval of eight weeks. 
 March 28, 2011
76 Post-text Supplement 4: WHO and MDACC Criteria for Response in 
Bone 
 
Response Type World Health Organization Definition1,2 
Complete Response 
(CR) Complete disappearance of all lesions on Xray or scan for at least 4 weeks 
Partial Response 
(PR) Partial decrease in size of ly tic lesions, recalcification 
of lytic lesions or decreased density of blastic lesions for at least 4 weeks 
No Change (NC) or 
Stable Disease (SD) 
 Because of the slow response of bone lesions, the classification of “no change” should not be applied 
until at least 8 weeks have passed since the start of 
therapy 
Progressive Disease 
(PD) Increase in size or extent  of lesions or appearance of 
new lesions 
Response Type MDACC Definition3 
Complete Response 
(CR)  Complete sclerotic fill-in of  lytic lesions on XR or CT 
Normalization of blastic lesions on XR or CT 
Normalization of tracer uptake on SS 
Normalization of signal intensity on MRI 
 
Partial Response 
(PR) Development of a sclerotic rim or partial sclerotic fill-in of lytic lesions on XR or CT 
Osteosclerotic “flare” -  Interval visualization of lesions 
with sclerotic rims or “new” sclerotic lesions in the setting of other signs of PR and absence of 
progressive bony disease  >
 50% decrease in measurable lesions on XR, CT or 
MRI Unequivocal decrease in the size of blastic lesions 
on XR or CT 
Unequivocal decrease in tracer uptake on SS  (verify 
 March 28, 2011
77 rapid response)  
No Change (NC) or 
Stable Disease (SD) 
 No change 
< 25% increase or < 50% decrease in measurable 
lesions 
No new lesions  
Progressive Disease 
(PD) > 25% increase in size of  measurable lesions on XR, 
CT or MRI 
Unequivocal increase in t he size of unmeasurable 
lytic or blastic lesions on XR, CT or MRI Unequivocal increase in tracer uptake on SS (verify 
flare) 
New bone metastases on CT or MRI or new 
symptomatic bone metastasis on bone scan  
 
1. Occurrence of bone compression or frac ture and its healing should not be used 
as the sole indicator fo r evaluation of therapy. 
2. Tumor Measurements : 
 Lesions will be selected by size from the longest diameter and will be measured in 
centimeters. 
 The longest diameter will be used for measured lesions. 
 Size will be reported as t he product of the diameters. 
3. Measurements are based on the sum of a perpendicular,  bidimensional measurement 
of the greatest diameters of each individual lesion 
 March 28, 2011
78  
Post-Text Supplement 5: Eastern Coope rative Oncology Group (ECOG) 
Performance Status 
 
 
Grade Description 
0 Fully active, able to carry on all pre-disease performance without 
restriction 
1 Restricted in physically strenuous activity but ambulatory and able to 
carry out work of a light or sedent ary nature, e.g., light housework, 
office work 
2 Ambulatory and capable of all self-c are but unable to carry out any 
work activities. Up and about more than 50% of waking hours.  
3 Capable of only limited self-care , confined to bed or chair more than 
50% of waking hours. 
4 Completely disabled. Cannot carry on any self-care. Totally confined 
to bed or chair. 
5 Dead 
 
 
 March 28, 2011
79 APPENDIX 1 LIST OF ABBREVIATIONS 
Abbreviation Term 
  
ANC Absolute Neutrophil Count 
BID Twice a Day 
CAT ( or CT scan) Computed Axial Tomography 
CBC Complete Blood Count 
  
CR Complete Response 
DLT Dose Limiting Toxicity 
DSMB Data Safety Monitoring Board 
ECG Electrocardiogram 
ECOG PS Eastern Cooperative Oncology Group Performance Status 
  
  
HIPAA Health Insurance Portability and Accountability Act 
HIV Human Immunodeficiency Virus 
IRB Institutional Review Board 
  
MRI Magnetic Resonance Imaging 
PD Progressive Disease 
  
PFS Progression Free Survival 
PO By Mouth 
PR Partial Response 
QD Once Twice daily 
QoL Quality Of Life 
RECIST Response Evaluation Criteria In Solid Tumors 
SAE Serious Adverse Event 
  
SD Stable Disease 
TNM Staging Tumor, Node and Metastasis Staging 
  
ULN Upper Limit of Normal 
WBC White Blood Count 
WOCPB  Women of Child-Bearing Potential 
 
 March 28, 2011
80 APPENDIX 2 KNOWN INDUCERS & INHIBITORS OF ISOENZYME 
CYP3A4 
Inducers  
Carbamazepine 
Dexamethasone Ethosuximide 
Glucocorticoids 
Griseofulvin Nafcillin 
Nelfinavir 
Nevirapine 
Oxcarbazepine 
Phenobarbital Phenylbutazone Phenytoin Primidone Progesterone 
Rifabutin 
Rifampin Rofecoxib (mild) 
St John’s wort 
Sulfadimidine 
Sulfinpyrazone 
Troglitazone 
Inhibitors 
Amiodarone 
Anastrozole 
Azithromycin 
Cannabinoids Cimetidine 
Clarithromycin 
Clotrimazole Cyclosporine 
Danazol 
Delavirdine Dexamethasone 
Diethyldithiocarbamate 
Diltiazem Dirithromycin 
Disulfiram 
Entacapone (high dose) 
Erythromycin 
Ethinyl estradiol Fluconazole (weak) 
Fluoxetine 
Fluvoxamine Gestodene 
Grapefruit juice 
lndinavir lsoniazid 
ltraconazole  
 Ketoconazole 
Metronidazole 
Mibefradil 
Miconazole (moderate) Nefazodone 
Nelfinavir 
Nevirapine Norfloxacin 
Norfluoxetine 
Omeprazole (weak) Oxiconazole 
Paroxetine (weak) 
Propoxyphene Quinidine 
Quinine 
Quinupristin and dalfopristin 
Ranitidine 
Ritonavir Saquinavir 
Sertindole 
Sertraline Troglitazone 
Troleandomycin 
Valproic acid (weak) Verapamil 
Zafirlukast 
Zileuton 
 
 March 28, 2011
81 APPENDIX 3 DASATINIB PATI ENT DIARY FOR STUDY:CA180094 
Your Study ID:  Your Doctor: Your Nurse: 
 Phone: Phone: 
Doctor’s instructions for dasatinib:  
Name of drug  Dosing  How Often  When  
Dasatinib ___# of 20 mg 
tablets ___# of 50 
mg tablets   ____  day ___After Breakfast 
___After supper 
 
 Cycle ____ Week of ________ to ________ 
Dasatinib dose (Check () when you take it)  
Insert Date  Monday Tuesday Wednesday Thursd ay Friday Saturday Sunday 
A.M. 
  20 mg 
 
 50 mg 
  20 mg 
 
 50 mg 
  20 mg 
 
 50 mg 
  20 mg 
 
 50 mg 
  20 mg 
 
 50 mg 
  20 mg 
 
 50 mg 
  20 mg 
 
 50 mg 
 
P.M.  20 mg 
 
 50 mg 
  20 mg 
 
 50 mg 
  20 mg 
 
 50 mg 
  20 mg 
 
 50 mg 
  20 mg 
 
 50 mg 
  20 mg 
 
 50 mg 
  20 mg 
 
 50 mg 
 
 
Notes (Anything you wish to tell your doctor/nurse?): 
 
 
 
 
 
 
 
 
 March 28, 2011
82 APPENDIX 4;  Study Management Plan 
 
1. Introduction  
The Study Management  Plan outlines the procedures  and requirements  for institutions  collaborating  
with UTMDACC  in the conduct of an Investigator  initiated trial  sponsored  by Bristol  Meyer  Squib. This 
plan is written  in adherence  to the overall BMO Medical Oncology  Monitoring  Plan.  
2. Purpose of a Protocol Specific Study Management  Pla n (SMP)  
To establish  standards  that will ensure compliance  with Federal Regulations,  Good Clinical Practice 
Guidelines;  and Health Insurance  Portability  and Accountability  Act and the Institutions  for both the 
lead and sub‐investigator  sites for MDACC Protocol 2006‐0900. 
 
3. General Roles and Responsibilities  of the Lead  Site 
 
Lead  Principal Investig ator’s  Role  
Stacy Moulder MD and/or designated  research  staff  is responsible  for: 
 Protocol Development : The coordination,  development,  submission,  and approval of the 
protocol as well as subsequent  amendments  by the IRB and study sponsor.  
 
 Study Oversight : PI and designee(s)  will monitor the progress and overall conduct of the study 
at all parti
cipating  institutions  through the regular review  of data. Data items to review  are as 
follows:  doctors  examination  for status of patients enrolled, eligibility,  status of treatment  
(on/off treatment,  any  dose modifications,  and dose delays), AE’s  and SAE’s, and response 
evaluation.  Also, included will be a review  of regulatory  and data manage ment documents,  
including any amendments,  memos regarding  status of approvals,  maintenance  of regulatory  
documents,  and queries.  
 Regulatory  Management : The lead site is responsible  for timely distribution  of approved  
protocols,  amendments,  revisions,  or status changes to participating  institutions.  Collaborating  
sites will be corresponded  with electronically,  unless traditional  mail  methods are requir ed. 
Main  methods of correspondence  will be email  or fax.  Outlook  calendars  will be created for 
each collaborating  site.  Required  correspondence,  expiration  dates, or any  dated  or timed 
events will be noted on the calendars  with a reminder  to send necessary  communication  
regarding  those events to collaborating  sites.  Maintenance  of regulato ry binders with 
information  from each site will be managed  by a BMO designee with the help of the calendars.  
All regulatory  documentation  will be received by the Department  of Breast Medical Oncology  
prior to initiation of any  protocol related procedures.  It is the participating  institution‘s  
responsibility  to notify its IR B of the above mentioned  events. 
 Registration/Enrollment  of Participants : the lead site will review the signed  informed  consent, 
the registration  form,  completed  eligibility CRF, Pathology  Report,  Relevant Scans and Labs. 
The registration  form will include the sub‐investigator’s  signature.   The participant,  if eligible, 
 March 28, 2011
83 will be registered  in MDACC Clinical Research Oncology  system (CORe).  BMO  will provide 
University  of Chicago/Duke  with confirmation  of eligibility,  registration  and our assigned Core 
Number within 48 hours.  If, however there is questionable  data submitted  to the department,  
source documents  will be requested  by Breast Medical Oncology  (BMO)  to verify and confirm 
participa
nt’s eligibility prior to enrollment.  If the participant  is deemed ineligible at the 
collaborating  site, they will be notified via written correspondence  (i.e. email, fax) as soon as 
possible, allowing for weekend/holidays  by noon of the next business day. 
 
 Data  Collection  and Management : the lead site will design and distribute  ca se report forms 
(CRF’s), monitor data quality, and issue queries via email  if necessary.  If 
questionable/conflicting  data has been submitted  to the department  by a collaborating  site, 
source documentation  will be requested  by BMO to verify the protocol specific data. Source 
documents  (i.e. such as an on‐study not e  will reflect the registration/consent/and  eligibility 
process). Baseline and eligibility data should be received by the lead site within 7 days of 
registration.  Protocol deviations  will be reported to the lead site according  to the collaborating  
site’s  IRB guidelines.  Violations  and serious adverse events will be reported within 24 hours of 
the resear
ch team being notified.  SAE’s should meet the guidelines  of prompt reporting  
(causality;  possible, probably,  definitely  related to study drug; serious and unexpected  adverse 
events.  The PI will notify the collaborating  sites of these SAEs within 24 hours. Violations  also 
need to be reported within 24 hours of the resear ch  team becoming  aware. External  Adverse 
Event will be emailed to collaborating  sites received from the supporter.  Response  evaluations  
will be made  available to the lead site every eight to 10 weeks.  Serious Adverse Events will be 
reviewed  by the Principal Investigator  at the lead site (BMO), and shared with all collaborati ng 
sites through written correspondence  (email). 
 CRF’s will be made  available electronically  to collaborating  sites. The lead site will enter data 
into the Protocol Data Management  System (PDMS) within a timely manner,  21 days from the 
date of submission).  
 BMO will assure that all collaborating  sites will provide MDACC with a copy of their IRB/IEC 
initial approval and conti
nuing review approvals.  
Miscellaneous Research Nurse Responsibilities 
Coordinates and participates in th e initiation meetings. Provides report s to the lead PI regarding the 
accrual, toxicities, and responses through the review of data.  . 
The lead site will request source documents or review documents already sent to BMO to monitor and 
audit participating institutions by the inspection of se lected patient records. Audits will be conducted at 
the lead site. Documents and procedures that w ill be examined will be the registration process, 
informed consent process, eligibility, treatment, protocol compliance, outcome and response, toxicity, 
data quality and the documenta tion of each. Appropriate regulator y documents and the reporting of 
deviations, violations, and required advers e events will be included in the review. 
Provide and maintain study contact list for all key personnel at each par ticipating institution.  
Ensure that a completed registration form and a copy of the signed Informed Consent are received at the lead site. 
 March 28, 2011
84 Ensure that eligible pa rticipants are registered on study at UT MDACC prior to the initiation of any 
study- related procedures, assessments or treatments.  
Collect relevant de-identified ra diology/nuclear medicine scans, la b, and pathology reports faxed or 
emailed to MDACC. These include CT Chest/Abdo men/Pelvis, Bone Scan and Survey, and MRI’s 
performed, and ECG.  
4. General Roles and Responsibilities  of the Collaborating  Site 
 
Participating  Institution  ollaborating  Investigator  Role :  
The investigator  and/or  designated  research  staff  is responsible  for compliance  in the following  areas: 
Protocol Management,  Regulatory  Management,  Data Collection  and Management.   
Protocol Management:  
 All regulatory  documentation  will be received by the Department  of Breast Medical Oncology  
prior to initiation  of any protocol related  procedures.   
 Source documentation  will made available to the le ad site to confirm protocol compliance  (i.e. 
protocol eligibility,  the informed  consent process, protocol directed  therapy compliance,  
adverse events,  response evaluation,  and other items as requested  per the CRF) and in 
accordance  with the Institution,  the code of Federal Regulations,  ICH, and Good clinical 
Practice. In addition the necessary  regulatory  items from each coll aborating  site will be shared 
in a timely manner with the lead site. 
 Appropriate  documentation  regarding  the investigational  nature  of the protocol and the 
alternative  diagnostic  or treatment  approaches  will be included. 
               Regulatory Management:   
 A list of key study personnel  and updates as needed on the delegation  authority  log. 
 Submission  of protocol and subsequent  amendments  to the local IRB prior to initiating any 
protocol changes or activity is the collaborating  sites responsibility.  
 Provide all required regulatory  documents  to the lead  site: such as  
 Lab CLIA’s  and CAP 
 1572  
 Training Log  
 Delegation  of Authority  Lo
g  
 Screening  Log  
 Subject Enrollment  Log 
 IRB Acknowledgement  of Investigational  Drug  Brochure/Package  Insert 
 Lab Normal Ranges 
 IRB/Institutional  Ethics Committee  approval of the Informed  Consent 
 Medical License 
 Curriculum  vitae 
 Financial Disclosures  
 Initial IRB Approval 
 March 28, 2011
85  Submission  of all external and internal SAE’s to local IRB with copies sent to the lead site. 
 Participating  sites will send the following  required regulatory  documents  post‐activation:  
 Annual Approval  Documents  (Continuing  Reviews) 
 Informed  Consent Revisions,   
 Serious Adverse Events  
 Evidence of the Participating  Institution’s  IRB review  of Ext ernal Safety Reports  
 Protocol Violations  and Deviations  Submitted  to the Participating  Institution’s  IRB.   
 Any document  that the study supporter  may  require. 
 
Data Collection  and Management   
 
The Research Nurse and/or Clinical Coordinator  and Data Manager  will assure adherence  to the 
protocol as noted in the source documentation  and submitted  as required:   
 
 Ensure that  all data is submitted  into  the database within 7 to 10 business days and in 
compliance  with data entry schedule  as outlined below:  
 Registration  Form and required documents  for enrollment  at the time  of registration.  
 All pre‐study data should be submitted  within  7 days of registration  
 Respond and resolve all da
ta queries generated  by the lead site within 3 weeks. 
 Submit all subsequent  protocol activity i.e. (doctor visits, treatments  or exams, adverse events, 
protocol data/off treatment  data) should be entered within 3 21 days of the event. 
 Lead Site will notify participating  sites of delin quent/incomplete  data.  
 Monitor / (QA) the completeness  of data entered  
 Obtain Required Regulatory  Documents  from Each  Site Post‐Activation.   
 annual approval documents  (continuing  reviews),  
 informed  consent revisions 
  Serious Adverse Events 
 Evidence of Participating  Institution’s  IRB review  of External Safety Reports 
 Protocol Violations  and Deviations  submitted  according  to the participating  
institution’s  IRB policy.  
 Any document  that the study supporter  may  require. 
 
5. Patient Confidentiality  an d Authorization  Statement:  
All institutions  involved in the trial  will attempt to limit  the use of PHI in its trials. However,  because  of 
the nature of these trials, certain PHI must be collected as per the sponsor requirements.  
 
6. Sub contract must be negotiated,  signed and executed  independently  between BMS and Universi ty 
of Chicago and Duke University.                
 March 28, 2011
86  
7. Correlative  Studies: 
Supplies will be provided and paid for by the collaborating  sites 
       Urine NTX levels will be performed acco rding to collaborating sites policy. 
                All research  lab samples (serum and tissue) will be processed  by the participating  institution.                      
 Samples will be shipped according  to the participating  sites shipping and handling policy to MDACC 
and will be stored in Dr. Francisco  Esteva’s lab at the expense of the collaborating  sites contract when 
accrual  is complete.     
 
              Sharell Cornet-Risher or Patricia Hutchinson CIT’s will accept shipment of samples.  
               Address to be used is:  
 
               The University  of Texas  M.D. Anderson  Cancer Center 
               Department  of Breast Medical Oncology,  Unit 1354 
               1155 Herman P. Pressler, CPB5.3450  
               Houston, Texas 77030‐3721 
 
 
 1. Hamaoka T, Madewell JE, Podoloff DA, Hortobagyi GN, Ueno NT. Bone imaging in metastatic breast cancer. J Clin Oncol 2004;22: 2942-53. 2. Amoroso V, Pittiani F, Grisanti S , et al.  Osteoblastic flare in a pa tient with advanced gastric 
cancer after treatment with pemetrexed and oxaliplatin: implications for response assessment with RECIST criteria. BMC Cancer 2007;7: 94. 3. Coleman RE, Mashiter G, Whitaker KB, Moss DW , Rubens RD, Fogelman I. Bone scan flare 
predicts successful systemic therapy fo r bone metastases. J Nucl Med 1988;29: 1354-9. 
4. Schneider JA, Divgi CR, Scott AM, et al. Flare on bone scintigraphy following Taxol chemotherapy for metastatic breast  cancer. J Nucl Med 1994;35: 1748-52. 
5. Janicek MJ, Hayes DF, Kaplan WD. Healing flare in skeletal metastases  from breast cancer. 
Radiology 1994;192: 201-4. 6. Vogel CL, Schoenfelder J, Shemano I, Haye s DF, Gams RA. Worsening bone scan in the 
evaluation of antitumor response during hormonal th erapy of breast cancer. J Clin Oncol 1995;13: 
1123-8. 7. Levenson RM, Sauerbrunn BJ, Bates HR, Newman RD, Eddy JL, Ihde DC. Comparative value of bone scintigraphy and radiography in monitoring tumor response in systemically treated prostatic carcinoma. Radiology 1983;146: 513-8. 8. Chao HS, Chang CP, Chiu CH, Chu LS, Chen YM, Tsai CM. Bone scan flare phenomenon in 
non-small-cell lung cancer patients treated with  gefitinib. Clin Nucl Med 2009;34: 346-9. 
9. Condon BR, Buchanan R, Garvie NW , et al. Assessment of progression of secondary bone 
lesions following cancer of the br east or prostate using serial radionuclide im aging. Br J Radiol 
1981;54: 18-23. 10. Arano Y. Recent advances in 99mTc ra diopharmaceuticals. Ann Nucl Med 2002;16: 79-93. 
 
 March 28, 2011
87  